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“Dopesick”: What is the Opioid Epidemic?
Roughly every 15 minutes, a mother gives birth to a baby suffering from opioid withdrawal
in the United States (Tribble, “For Babies Of The Opioid Crisis, Best Care May Be Mom's
Recovery”). Treating infants experiencing withdrawal is just half the battle of the opioid
epidemic overwhelming pregnant women of the nation. According to the Centers for Disease
Control and Prevention (CDC), the number of pregnant women diagnosed with opioid use
disorder (OUD) in hospital labor and delivery units more than quadrupled between 1999 and
2014 (News Staff, “Number of Women With OUD in Labor/Delivery Quadruples”).
Furthermore, the national average of OUD among women in this group increased from 1.5 per
1,000 delivery hospitalizations in 1999 to 6.5 per 1,000 delivery hospitalizations in 2014 (News
Staff, “Number of Women with OUD in Labor/Delivery Quadruples”). The opioid epidemic has
devastated all races and classes in the past decade, an undeniable fact (Bowman, “The Viral
Obituary of an Opioid Addict: 'She's Just One Face' Of The Epidemic”). Yet, the government did
not declare the opioid crisis a public health emergency until the end of October 2017 (Christie 5).
Thousands of people are dying from drug overdoses each year, and now an increasing number of
infants are facing the largely unknown consequences of opioid exposure and withdrawal.
The most striking element of the opioid epidemic is simply that these facts are not really new
– the problem has been culminating for at least 20 years. It is 2019 and still the opioid epidemic
claims an estimated 115 lives each day (Bowman, “The Viral Obituary Of An Opioid Addict:
'She's Just One Face' Of The Epidemic”). With vulnerable women and children making up a
large portion of those suffering from the opioid crisis, it is time to overcome stigma and start
examining successful and plausible solutions. Personal accounts of those brave enough to share
their struggles can make profound impacts for pathways to change.
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An obituary of a young woman, Madelyn Ellen Linsenmeir, that went viral in 2018, captures
the raw and real story of a woman and her child battling the monster of addiction. Linsenmeir’s
sister, Kate O’Neill, wrote Madelyn’s obituary in her honor. Linsenmeir started her fight with
addiction in 2004 at the young age of 16 when she tried OxyContin at a high school party for the
first time. When her son Ayden was born in 2014, her sister writes, “After having Ayden [,]
Maddie tried harder and more relentlessly to stay sober than we have ever seen anyone try at
anything. But she relapsed and ultimately lost custody of her son, a loss that was unbearable”
(O’Neill, “Madelyn Ellen Linsenmeir”). Loss of parental rights is a huge fear many addicted
mothers face, discouraging them from seeking treatment in many cases. In this obituary, O’Neill
not only captures the real struggles of her sister, she accurately describes how the world around
Madelyn made it even harder for her to keep fighting her addiction. O’Neill declares, “To some,
Maddie was just a junkie – when they saw her addiction [,] they stopped seeing her. And what a
loss for them” (O’Neill, “Madelyn Ellen Linsenmeir”). The perception of those battling addiction
as “junkies” acts as a persistent barrier to proper treatment. Even physicians are not immune to
biases about patients battling with addiction, which can make it increasingly difficult to connect
women with the care they need. Mothers with OUD especially are seen as bad mothers who do
not care about their children and should not be able to keep them in their custody. The tragic
story of Madelyn Ellen Linsenmeir’s battle with drug addiction identifies important gaps in the
treatment of addiction in the United States, and also offers an opportunity to reevaluate health
care services in a time of need.
Madelyn’s obituary received a lot of heartfelt attention from the public, which her sister
explains with the following reasoning: “It’s their story, or the story of their neighbor, or the story
of their daughter, or the story of their coworker’s daughter” (qtd in Bowman, “The Viral
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Obituary Of An Opioid Addict: 'She's Just One Face' Of The Epidemic”). It is easy to critique the
sudden response from the public about an epidemic that has plagued the nation for so many
years, but the reality is that there are so many other women and children like Madelyn and her
son Ayden. If it is stories such as these that bring more national attention to a devastated part of
the health sector, then more accounts and facts need to be published to fuel motivation to devote
resources to researching the most successful treatment methods.
An increasing amount of literature identifies the overwhelming national opioid problem with
specific foci on pregnant women and infants. However, at the same time that news articles are
being released on survivor stories and promising treatment methods, statistics are still
accumulating deaths from opioid overdose and misuse. Society has not progressed enough in
tackling this devastating crisis. The realization that the pharmaceutical industry is largely
responsible for the nation’s access to opioids in partnership with the urged shift to understand
addiction as a chronic disease both have just occurred, yet a few years too late. In addition to the
constructive research being published on the opioid epidemic and how society can overcome it,
change must be enacted. It is time for society to face the overwhelming treatment demand and
deploy underutilized resources that can provide aid to all those in need. Women of childbearing
age specifically and their children face many unique and difficult challenges of the opioid
epidemic. Pregnant women have been largely left out of research studies because of ethical
concerns and stigma has continuously influenced women battling drug addiction to feel shame
and not seek treatment. Therefore, infants are also suffering the effects of withdrawal without
proper care. In consideration of all the areas of society and people the opioid epidemic damages,
there cannot be an efficacious “one size fits all” treatment model. Women and children need a
comprehensive treatment approach that connects them with the care they need, while also
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working towards diminishing stigma and other inequalities. This literature synthesis examines a
thorough timeline of the opioid epidemic, including: the history of the opioid epidemic in the
United States; its notably harmful effects on women and children; systematic barriers that have
left thousands of women and children struggling with drug addiction untreated in society today;
and the advantages and disadvantages of an array of treatment methods that have not been
predominantly successful in reducing the burden of the epidemic. The paper concludes with a
case study of a pilot program that has taken an ideal, holistic approach to treating mothers and
their infants.
The case study features the program CARE Plus, a research program located in Indianapolis,
Indiana, one of the many cities facing detrimental consequences from the opioid crisis. While
CARE Plus is one of the first of its kind specifically designed for women battling opioid use
disorder, Indianapolis has also had previous successes with other peer modeled programs
attempting to fill many resource gaps. CARE Plus is a unique treatment approach, structured
from the peer model, built on women empowerment and the mission to equate substance use
disorders on the same plane as all other chronic illnesses, such as diabetes or cancer. This
literature synthesis concludes with a close analysis of CARE Plus in order to put into perspective
all of the different elements discussed around holistic treatment and portray progress in
efficaciously battling the opioid epidemic. CARE Plus could act as motivation and an example
model for further reform. First, it is crucial to understand opioids, how they work, and just how
seriously they have affected society.
Substance use disorders affect everyone. Societal barriers render treatment ineffective in
regard to accessibility and availability for all, perpetuating the nation’s opioid crisis. Policy
makers, health care and social justice activists must strategically focus on the most vulnerable
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populations in order to significantly reduce this epidemic’s disease burden. Considering the
breadth of addiction, it is seemingly impossible to determine where to begin. Pregnant women,
for example, are one group of opioid victims whose struggles are even further intensified by
substance use disorders. The stigma and legal ramifications that surround pregnant women and
mothers who abuse drugs is at least doubled in strength because there are two lives at stake in
these cases. With increased focus on addicted pregnant women, progress for reduction of the
opioid crisis can be achieved for two critical groups: the nation’s women and children.
According to a CDC report from 2018, since 1999 opiate overdose deaths have increased
265% among men and 400% among women (“Prescription Painkiller Overdoses”). The umbrella
term opioid covers a wide range of addictive substances. An opioid is a drug which binds to
opioid receptors in the body (Truth, “What Are Opioids?”). The term “opioids” covers illegal
substances as well as prescription drugs for pain relief, ranging from heroin to hydrocodone,
more commonly known as Vicodin. Opioids reduce the perception of pain but can also cause
drowsiness, confusion, euphoria, nausea, and constipation, and possibly depress respiration
(SAMHSA, “Substance Use Disorders”). People commonly misuse opioids by snorting or
injecting them as an attempt to intensify the drug’s pleasurable effects. These methods increase
the risk for serious medical complications, such as HIV infection from unsterile needles or
overdose (SAMHSA, “Substance Use Disorders”). Symptoms of opioid use disorders, similar to
other substance use disorders, include a strong desire for opioids, inability to control or reduce
use, continued use despite interference with major obligations or social functioning, increases in
amounts and frequency of use, development of tolerance, focusing and spending large portions
of time obtaining and using opioids, and experiencing withdrawal symptoms from stopped usage
(SAMHSA, “Substance Use Disorders”). On top of the devastating physical risks of opioid use
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disorder, addiction is a chronic disease often associated with intense mental health problems,
such as depression, anxiety and mood disorders (O’Brien and Crowley 546).
The opioid epidemic is severe in several areas of society; politically, economically, and
especially in the health care sector. Opioid use disorder, a subcategory of substance use
disorders, is associated with a significant disease burden and the highest mortality among all
mental and behavioral disorders (World Health Organization, “Alcohol and Drug Use Disorders:
Global Health Estimates”). Long-term effects of opiates include liver and brain damage and
dependence, arguably the most significant. Paired with their highly addictive qualities, opioids
are easy to obtain through medical prescriptions, which is a highly dangerous partnership
(Patterson, “The Effects of Opiate Use”). In 2017, the CDC estimated that roughly 70,000 people
died from drug overdoses (CDC, “Opioid Overdose”); however, this number is likely low due to
underreporting. Opioids are the most abused illicit drugs in the United States (Patterson, “The
Effects of Opiate Use”). Today, the U.S. alone makes up 5% of the world’s population but
consumes almost 70% of the global opioid supply (Rieder, “The Agony of Opioid Withdrawal and What Doctors Should Tell Patients about It”). Americans have a 1 in 96 chance of dying
from an opioid overdose. For the first time in U.S. history, this probability has surpassed another
leading cause of death: vehicle crashes, with the likelihood of a 1 in 103 chance of dying
(Stewart, “Report: Americans are Now More Likely to Die of an Opioid Overdose than on the
Road”). Women, specifically pregnant women, make up an unacceptable portion of these
numbers. In addition to the direct effects of OUD, there are other comorbid complications which
are important to consider in the breadth of the epidemic and efficacious treatment programs.
OUD is often comorbid with mental health illness or dangerous use of other substances.
Almost half of people who experience SUD in their lifetime will also experience a mental illness
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(National Institute on Drug Abuse, “Comorbidity: Substance Use Disorders and Other Mental
Illnesses”). Additionally, some mental health illnesses have been established as risk factors for
developing SUDs (National Institute on Drug Abuse, “Comorbidity: Substance Use Disorders
and Other Mental Illnesses”). Substance use disorders in general are not well treated in American
society. It has been reported that “nearly half of all Americans who have a severe mental illness
fail to seek treatment” (Stephenson 325). The problems concerned with SUDs are parallel with
OUDs and magnified with the current wave of the opioid crisis. To fully understand OUD, it is
important to examine the pathophysiology of addiction and the overall structural inequalities that
have failed to accurately address the opioid epidemic.
Addiction
Although the National Institute on Drug Abuse defines addiction as a chronic disease that can
be managed and treated successfully, substance use disorders are not widely accepted as medical
illnesses (Krans and Patrick, “Opioid Use Disorder in Pregnancy”). The misconceptions of
addicted persons being morally weak or lacking willpower are still very prevalent in society
today (Olsen and Sharfstein, “Confronting the Stigma of Opioid Use Disorder – and Its
Treatment”). The debate “Choice or illness?” still exists, even though only one side is supported
by scientific evidence. This debate is intensely present amongst pregnant women and mothers,
and historically has been an influential factor in portraying women as bad mothers who do not
care about their children if they abuse drugs. Further, addiction treatment that utilizes medication
to taper off of opioids is seen as replacing one addiction for another. Many concerns exist around
new mothers taking drugs such as methadone and buprenorphine to treat opioid use disorder and
effects on their infants. Evidence supports, however, that medication-assisted treatment (MAT) is
safe for pregnant women (Klaman 2). Data also proves that breast milk contains minimal traces
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of these treatment drugs, and breastfeeding is endorsed for new moms (Kocherlakota 554).
Generally, MAT increases patient retention, and decreases drug use, infectious disease
transmission, and criminal activity (Olsen and Sharfstein, “Confronting the Stigma of Opioid
Use Disorder – and Its Treatment”). Addiction is not a weakness or choice, yet this is only one of
the battles with stigma that people combating OUD continue to face in society today.
The American Society of Addiction Medicine defines addiction as a “primary, chronic
disease of brain reward, motivation, memory and related circuitry” (ASAM, “Definition of
Addiction”). Addiction is also characterized by:
…the inability to consistently abstain, impairment in behavioral control, craving,
diminished recognition of significant problems with one’s behaviors and interpersonal
relationships, and a dysfunctional emotional response. Like other chronic diseases,
addiction often involves cycles of relapse and remission. (ASAM, “Definition of
Addiction”)
Depending on the source, addiction has been characterized as either a chronic disease, a mental
illness (National Institute of Mental Health), a brain disease (American Psychiatric Association),
and even personal weakness. For the purpose of this paper, addiction is discussed and referred to
as a medical, physiologic disease. Pregnant women face intensified stigma around drug use,
pregnancy, and motherhood. Viewing addiction as a chronic disease underscores that addiction
does not involve a moral problem and focuses the goal of treatment away from a “quick cure” to
“long term management” (American Society of Addiction Medicine, “Treating Opioid Addiction
as a Chronic Disease”). Understanding addiction is the first step in understanding opioid use
disorder and how to treat it.
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A substance use disorder is a cluster of cognitive, behavioral and physiologic symptoms
indicating that the individual continues to use the substance despite significant substance-related
problems (O’Brien and Crowley 483). An underlying change in brain circuits that can persist
beyond the detox period, especially in individuals with a severe disorder is an important
characteristic of substance use disorders (O’Brien and Crowley 483). Substance use disorders are
chronic illnesses for which there is no cure (Olsen and Sharfstein, “Confronting the Stigma of
Opioid Use Disorder – and Its Treatment”). Different types of substance use disorders include
alcohol, tobacco, cannabis, stimulant, hallucinogen, and opioid use disorder. The DSM-5 from
the American Psychiatric Association has moved away from terms such as “opioid abuse” and
“opioid dependence” to the more current, accepted classification of the disease as “opioid use
disorder.”
There are 11 criteria for diagnosing a substance use and opioid use disorder. In order to
be diagnosed with opioid use disorder, two of the following must occur within a year. Criteria 14 are categorized as impaired control, including taking the opioid in larger amounts or for longer
than initially intended, having a persistent desire to reduce or control usage without success,
spending a lot of time obtaining the opioid or recovering from its effects, and craving (O’Brien
and Crowley 541). Criteria 5-7 are classified as social impairment, which is failure to fulfill
work, school, or personal obligations, using the opioid despite social or personal problems
manifesting from use of the substance, and backing out of important personal, occupational, or
social events (O’Brien and Crowley 541). Criteria 8 and 9 are named risky use for using the
substance when it’s physically dangerous and using even with awareness of having a persistent
psychological problem most probably stemming from use of the opioid (O’Brien and Crowley
541). Finally, criteria 10 and 11 are labeled as pharmacological, for developing a tolerance for
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the opioid and the experience of withdrawal in someone who has maintained prolonged heavy
use of the substance (O’Brien and Crowley 541). Opioid use disorders are qualified as mild,
moderate, or severe, with mild classified as experiencing 2-3 symptoms, moderate experiencing
4-5 symptoms, and severe experiencing 6 or more symptoms (O’Brien and Crowley 542). There
are important genetic and physiological factors that influence the risk for opioid use disorder.
The DSM-5 recognizes the important role genetic factors play, both directly and
indirectly, pertaining to an individual’s family, peer, and social environmental factors for risk of
developing an opioid use disorder (O’Brien and Crowley 543). Impulsivity is an individual
behavior that relates to the risk of developing a substance use disorder that could be genetically
determined (O’Brien and Crowley 543). A study from the Department of Psychiatry at the
University of Texas focusing on chronic pain patients provides evidence to support that opioid
individuals are more impulsive. They found that greater impulsivity is associated with greater
risk for misusing opioid analgesics (Marino 2156). Their findings suggest that impulsivity may
be a risk factor for opioid misuse with direct clinical implications (Marino 2156). Beyond
genetic factors, culture-related diagnostic issues also play a role in the development of addiction.
The DSM-5 explains that over time, OUD is seen more often among white middle-class
individuals, especially females (O’Brien and Crowley 544). This suggests that the different uses
of opioids reflect the availability of the drugs and that other social factors may also impact
prevalence (O’Brien and Crowley 544). The high cultural and social risk of addiction for females
is important in the availability and accessibility of treatment programs for all socioeconomic
classes and races.
Additional health risks to OUD exist that are important to include and address in treatment
programs. Because opioids can be injected for a faster high, users who inject are at increased risk
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for bacterial endocarditis, hepatitis, and human immunodeficiency virus (HIV). Bacterial
endocarditis is an infection caused by bacteria in the bloodstream that settle in the heart lining, a
heart valve, or a blood vessel (American Heart Association, “Heart Valves and Infective
Endocarditis”). Hepatitis is an inflammation of the liver. HIV is the weakening of a person’s
immune system with the destruction of important cells that fight disease and infection; it does
not have a cure (CDC, “HIV/AIDS”). The DSM-5 reports that HIV infection is as high as 60%
among heroin users (O’Brien and Crowley 545). Further, Hepatitis C infection may occur in up
to 90% of people who inject opioids (O’Brien and Crowley 545). The DSM-5 also reports the
prevalence of tuberculosis (TB), a disease of the lungs, in heroin users (O’Brien and Crowley
545). Anyone who utilizes the method of injection is at risk for these severe health conditions.
There are many additional serious risks that accompany OUD which are important to consider in
the holistic treatment process.
Withdrawal symptoms can include a severe group of symptoms that occur from the sudden
removal or abrupt decrease in drug usage (Condron, “Drug Withdrawal”). The DSM-5 also
classifies withdrawal as the administration of an opioid antagonist, such as naloxone, an
overdose reversal drug, after a period of opioid use (O’Brien and Crowley 547). Withdrawal is
diagnosed through the presentation of three or more of the following symptoms: dysphoric
mood, nausea or vomiting, muscle aches, lacrimation or the secretion of tears, rhinorrhea or
runny nose, pupillary dilation, piloerection or goose bumps, sweating, diarrhea, yawning, fever,
or insomnia (O’Brien and Crowley 547). Withdrawal cannot only be very dangerous for the
person enduring it, but also for the fetuses of pregnant mothers who can endure serious levels of
distress. Withdrawal is not recommended for pregnant women. The dangerous physical health
risks associated with withdrawal are so terrible that someone might risk death to avoid
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withdrawal, National Public Radio (NPR) reports (Feldman, “Opioid Antidote Can Save Lives,
but Deciding When to Use It Can Be Challenging”). Journalist Nina Feldman observes, “Many
people who use drugs say withdrawal is like having the worst flu of your life, complete with cold
sweats, shakes, and vomiting” (“Opioid Antidote can Save Lives, but Deciding when to Use It
can be Challenging”). In many cases, withdrawal is avoided at whatever the cost. The experience
of withdrawal is absolutely crucial to incorporate into treatment programs for women of
childbearing age.
It is necessary to look beyond traditional biomedical treatment practices at the underlying
social, emotional, and economic conditions in women’s lives that provide the context in which
chemical dependency develops and in which a woman and her family can recover (Finkelstein
1298). It is crucial to remember that when analyzing these statistics, the effects of an incurable,
chronic disease are the primary elements. In her discussion of preventable perinatal risks, Mary
P. Abernathy, a maternal and fetal medicine doctor, defines substance abuse as a chronic disease
similar to hypertension and obesity which requires ongoing treatment and management for the
rest of the patient’s life (“Infant Mortality, Substance Use and Abuse in Pregnancy”). The
common medical term “follow-up” becomes more than just regulatory post-treatment check-ups,
but consistent positive and sustainable management. Relapse should be an expected and focused
element of the treatment process; it does not mean treatment has failed. The National Institute on
Drug Abuse (NIDA) compares relapse rates between substance use disorders and other chronic
illness, such as hypertension and asthma. The rate of relapse for substance use disorders is
between 40%-60%, and the rate of relapse for both hypertension and asthma is between 50%70% (National Institute on Drug Abuse, “Treatment and Recovery”). Addiction is a complex
disease which requires sustainable, arguably lifelong treatment programs and practices which are
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equipped to deal not just with all facets of individual disorders, but also all groups of people
specific to gender and class.
The Youngest, Most Vulnerable Victims: Special Needs and Challenges of Pregnant
Women with Opioid Use Disorder
In the 1960s, over 80% of patients seeking treatment for opioid addiction were men
living in inner city, urban areas and who used heroin (Krans and Patrick, “Opioid Use Disorder
in Pregnancy”). In 2010, however, the majority of patients entering treatment programs were
middle-class women living in less urban or rural areas (Krans and Patrick, “Opioid Use Disorder
in Pregnancy”). Opioid use during pregnancy has increased nearly five-fold in recent years
(Angelotta 595). Between 2007 and 2016, pregnancy-related deaths due to opioid misuse more
than doubled (Gemmill 115). Additionally, from 2013 to 2014 the number of women of
childbearing age, defined as ages 15-44, who reported past-month misuse of prescription pain
relievers, such as OxyContin, increased to 98,000, or 5.3%, from 2011 to 2012 (Johnson and
Campopiano 2). In the same period, the number of women ages 15-44 who reported past-month
heroin use increased to 109,000, or 31%, in the same period (Johnson and Campopiano 2). The
CDC estimates that “one-third of reproductive-age women enrolled in Medicaid and more than a
quarter of those with private insurance filled a prescription for an opioid pain medication each
year between 2008 and 2012” (Johnson and Campopiano 2). According to SAMHSA’s “Clinical
Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and their
Infants”: “The prevalence of opioid use disorder (OUD) during pregnancy more than doubled
between 1998 and 2011 to 4 per 1,000 deliveries” (Johnson and Campopiano 2).
Even with all of these published statistics, pregnant women still are rarely connected with
and receiving the proper care they need. In Indiana in 2016, for example, only 69.4% of pregnant
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women received prenatal care in the first trimester (Box, “Where Indiana Stands: NAS and the
Opioid Epidemic). Women of reproductive age and neonates are an extremely vulnerable
population to the nation’s persisting opioid epidemic. Statistics only begin to paint the picture of
the battle of the opioid epidemic for the nation’s pregnant women.
Without treatment, pregnant women with OUD are at risk of preterm delivery, low infant
birth weight, and transmitting human immunodeficiency virus (HIV) to their infants (Johnson
and Campopiano 2). Many people with OUD who use prescription drugs switched to heroin
because of cost and ease of injections, as well as the recent proximity and established drug
trafficking infrastructure that has significantly reduced the price of heroin in the United States
(Krans and Patrick, “Opioid Use Disorder in Pregnancy”). It has been recorded that over 66% of
pregnant women on medication-assisted treatment (MAT) report a history of heroin use, and an
estimated 63% report a history of intravenous use, making HIV and other infectious diseases of
extreme concern (Krans and Patrick, “Opioid Use Disorder in Pregnancy”). Hepatitis C virus
(HCV) is another common infectious disease in pregnant women with OUD because of high-risk
sexual behaviors and intravenous drug use (Hand 225). As of 2017, rates of HCV among
pregnant women with OUD were between 50% and 62% (Hand 225). Pregnancy is a critical
opportunity to identify and evaluate HCV and HIV infections in high-risk populations (Hand
225).
Furthermore, the misuse of other substances in pregnant women with OUD including
alcohol, marijuana, cocaine, and tobacco may exacerbate the symptoms of neonatal abstinence
syndrome (NAS) (Hand 225; Johnson and Campopiano 47). For example, one study notes that
the “concomitant use of benzodiazepines [a class of psychoactive drugs] and opioids during
pregnancy is of particular concern as it increases the risk for maternal overdose and overdose
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death” (Hand 62). 13% of pregnant women in the South analyzed in this study reported
benzodiazepine use at enrollment (Hand 62). This portion is likely low due to other reports of
benzodiazepine use in the same population amounting to as high as 70% (Hand 62). Concomitant
use of other drugs, especially in pregnant women with OUD, is a critical area further supporting
the need for holistic treatment options. Significantly, a tobacco-use cessation program is one of
the most important therapies to begin when a woman enters OUD treatment (Johnson and
Campopiano 39). Heavy daily smoking during pregnancy is associated with compromised birth
outcomes and the degree of NAS the baby may experience (Johnson and Campopiano 39). The
risks associated with OUD, as well as other dangerous behaviors the addiction can influence,
specifically for mothers and babies, has led the nation to declare a public health crisis in response
to the opioid epidemic.
Maternal substance use contributes to the 50% of infant mortality perinatal risks that are
largely preventable, according to Mary Pell Abernathy, a maternal-fetal medicine doctor in
Indiana (“Infant Mortality, Substance Use and Abuse in Pregnancy”). As reported by the World
Health Organization (WHO), “The perinatal period commences at 22 completed weeks, or 154
days, of gestation and ends seven completed days after birth” (“Maternal and Perinatal Health”).
Perinatal risk factors include women’s health and behaviors before and during pregnancy which
can impact the health of their children (U.S. Department of Health and Human Services, “Child
Health USA 2013”). These risks range from low birth weight, no prenatal care or lack of early
prenatal care, not breastfeeding, preterm birth, smoking, substance use and abuse, diabetes, and
uncontrolled hypertension (Abernathy, “Infant Mortality, Substance Use and Abuse in
Pregnancy”). While NAS is rarely fatal, the condition is associated with preterm birth and low
birth weight. Additionally, women with opioid use disorder are more likely to use other
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substances, such as tobacco, and less likely to seek prenatal care in fear of the consequences.
Infant mortality is an important factor to consider when analyzing the severity of pregnancy and
the opioid epidemic.
Indiana, for example, falls at the bottom 20% of all states regarding infant mortality,
making it one of the worst states ranked for this frontline measure of health (Abernathy, “Infant
Mortality, Substance Use and Abuse in Pregnancy”). Indiana was also classified by the CDC as a
state showing no significant change in infant mortality between 2005-2011. However, infant
mortality reduction did not become a top state priority until January of 2013 (Abernathy, “Infant
Mortality, Substance Use and Abuse in Pregnancy”). Indiana’s most current infant mortality rate
for 2018 of 7.4 deaths per 1,000 live births is significantly higher than the Healthy People 2020
goal of 4.5 deaths per 1,000 live births (Abernathy, “Infant Mortality, Substance Use and Abuse
in Pregnancy”). The most frequent cause of infant death is low birth weight/prematurity (Indiana
State Department of Health, “Indiana Infant Mortality and Morbidity Annual Report”), one of
the top risks for pregnant women with OUD who do not receive treatment (Johnson and
Campopiano 2). OUD is a critical disease to target in order to save and improve the lives of
pregnant women battling with addiction and their newborns.
Alongside the important physical risks of substance use during pregnancy, women also
face emotional trauma and stigma. For example, Amanda Hensley, a 25-year-old mother of two,
was rejected by two hospitals and several clinics while struggling with a relapse during her
second pregnancy, a 2016 NPR article reports (Tribble, “Pregnant and Addicted: The Tough
Road to Family Health”). Even her immediate support system had abandoned her prior to her
refusal from medical attention. The father of her child, Tyrell Shepherd, described his
unhappiness with Hensley’s addiction: “If you don’t care about yourself, have enough common
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decency to care about the baby you’re carrying” (qtd in Tribble, “Pregnant and Addicted: The
Tough Road to Family Health”). Without a support system that understands addiction, seeking
treatment becomes infinitely harder for pregnant women who feel alone and judged.
Kelly Zimmerman, a 26-year-old mother, faced many similar struggles after the birth of
her son Jaxton. Kelly was a single mom grieving the death of her husband who had died just
months before the birth from a heart attack (Chatterjee and Davis, “Beyond Opioids: How A
Family Came Together To Stay Together”). As a struggling woman with OUD, Kelly was
receiving methadone to help treat her addiction, and her son was born with NAS (Chatterjee and
Davis, “Beyond Opioids: How A Family Came Together To Stay Together”). With the help from
her family and the accessibility of the program Family Group Decision Making, Kelly was able
to keep the custody rights of her son and receive proper treatment for OUD, which is not possible
for many pregnant women like Kelly. Society still holds unrealistic expectations for women,
especially of childbearing age, that puts sole responsibility on their shoulders. Hendrée Jones,
executive director at Horizons, a residential substance use disorder treatment program, succinctly
explains how society views mothers with OUD: “They’re supposed to automatically know how
to be ‘good mothers’ – how to be nurturing mothers. That’s like trying to teach somebody
algebra when they’ve never even had addition” (qtd in Tribble, “For Babies of the Opioid Crisis,
Best Care may be Mom’s Recovery”). Amanda and Kelly are just two examples of women
suffering from not just opioid use disorder, but the unrealistic expectations of society. Stigma
and the emotional trauma associated with OUD do not foster a safe environment for pregnant
women in America to seek treatment. This barrier prevents proper care from reaching infants
with NAS as well.
Neonatal Abstinence Syndrome (NAS)
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NAS is the second half of the battle that pregnant women and mothers face because of
OUD. In 2014, 657 infants in Indiana were born with neonatal abstinence syndrome (NAS). A
lack of data, underreporting, and a limited understanding of the effects of NAS make it likely
that the true number of cases was higher (Abernathy, “Infant Mortality, Substance Use and
Abuse in Pregnancy”). Neonatal abstinence syndrome, or NAS, is a result of the sudden
discontinuation of fetal exposure to substances that were used or abused by the mother during
pregnancy (Kocherlakota 548). NAS presents a range of potential adverse outcomes for the fetus
and infant, including preterm birth, low birth weight, respiratory, gastrointestinal, and central
nervous system disturbances (Falletta 126). Although NAS is rarely fatal, significant illness can
occur as well as prolonged hospital stays (Kocherlakota 548). Initial symptoms of NAS include
tremors, irritability, excessive crying and diarrhea (Logan 186). Seizures can also occur, but
evidence shows that central nervous system signs, such as tremors and excessive crying,
normally appear first (Kocherlakota 550). NAS is treated first with nonpharmacological care,
then pharmacological care depending on the severity of the condition.
Unfortunately, no perfect scoring system exists to determine the severity of NAS. There are
many scoring systems that have been developed, however, and the modified Finnegan Neonatal
Abstinence Severity Scores is currently the most common tool used (Logan 187). Advantages of
scoring for term infants include defining when and if pharmacological intervention is needed and
assistance with monitoring the defined therapy (Logan 187; Kocherlakota 553). Risk factors for
the severity of NAS include if the infant was born at full term, a healthy birth weight, polydrug
use, male gender, and tobacco and methadone use (Kocherlakota 553). Little research has been
done on the comparative cost-effectiveness of NAS scoring scales or their efficiency in
identifying opioid-exposed infants at birth (Johnson and Campopiano 79), such as the Lipsitz
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Tool (Neonatal Drug Withdrawal Scoring System) or MOTHER NAS (a modified Finnegan
Scale). Scoring systems help with management of the neonate in the administration of both
nonpharmacological and pharmacological care.
Nonpharmacological care includes practices such as gentle handling, demand feeding,
swaddling and careful avoidance of waking up the sleeping infant (Kocherlakota 553).
Breastfeeding is a form of nonpharmacological treatment that has many benefits for mom and
baby. The benefits of breastfeeding include an increase in bonding between mother and infant, an
enhancement in maternal confidence, and an encouragement in active maternal participation in
caretaking of the infant (Kocherlakota 555). In fact, breastfeeding can decrease the incidence of
NAS, a need for pharmacological treatment, and length of hospital stay (Kocherlakota 555).
Breastfeeding is a beneficial treatment for NAS for both baby and mom. There is significant
evidence to support the fact that breast milk only contains small quantities of methadone and
buprenorphine (Kocherlakota 554). Although the amount of buprenorphine and methadone
present in breast milk is not enough to treat NAS, breastfeeding can still be a helpful
nonpharmacological practice for baby that should continue even if the baby should need
pharmacological assistance. Importantly, the sudden discontinuation of breastfeeding is not
associated with increased severity of NAS. In general, however, gradual weaning from breast
milk is encouraged (Kocherlakota 555).
The avoidance of pharmacological care is considered a success largely for two reasons. First,
earlier discharge from the hospital is probable and second, there is additional risk due to the fact
that there is not a standard accepted pharmacological intervention for the management of NAS
(Kocherlakota 554). Realistically, medical intervention is required for 50% to 70% of infants
suffering from NAS (Logan 187). Morphine is the most common pharmacological intervention

21

for babies suffering from NAS, because it decreases seizures, improves feeding, eliminates
diarrhea and decreases agitation (Kocherlakota 554). Evidence shows that morphine is safer and
more suitable for infants with NAS (Kocherlakota 554); however, because it needs to be
provided every three to four hours, it increases lengths of hospital stays and costs. Neonatologist
Dr. Prabhakar Kocherlakota recommends an algorithmic approach for the management of NAS
because “no single medication is suitable for every patient and no single regiment is acceptable
to every patient” (554). Additionally, this approach is advantageous for community hospital
settings caring for infants with NAS and their mothers (Kocherlakota 554). Treatments and
assessment of both short-term and long-term damage from NAS are difficult to determine
because of the little knowledge of how, exactly, infants are affected by their mothers’ use of
opioids.
The pathophysiology of NAS is not completely understood (Kocherlakota 549). There is
limited knowledge even in adults about the complex cellular and molecular mechanisms of
opioid withdrawal (Kocherlakota 550). This process is further complicated in neonates because
of their “immature neurologic development, impaired neurological processing,” and complex
relationship between drug consumption and effects between mother and child (Kocherlakota
550). There are many factors that can affect opioid accumulation in the fetus. Opioids are easily
transferable across the placenta to the fetus because they are water soluble, are lipophilic, or
dissolvable, substances, and they have low molecular weights (Kocherlakota 550). Synthetic
opiates, such as fentanyl and methadone, cross the placenta more easily in comparison to
semisynthetic opiates, such as oxycodone and hydrocodone (Kocherlakota 550). According to
Kocherlakota, “A lack of opioids causes increased production of norepinephrine, which is
responsible for most of the signs of NAS” (550). Norepinephrine is an organic chemical in the
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body that acts as both a stress hormone and a neurotransmitter, or a substance that sends signals
between nerve cells (Cassata, “What is Norepinephrine?”). Norepinephrine plays a role in the
infant’s experience of excessive crying, agitation and irritability.
Opioid withdrawal affects the autonomic and peripheral nervous systems (Kocherlakota
550). Opioid withdrawal causes decreased serotonin expression, leading to sleep disturbances
(550). The autonomic nervous system is in charge of subconscious bodily functions such as the
control of breathing, heartbeat, and digestive system, and the peripheral nervous system controls
nerves outside of the brain and spinal cord. Interestingly, the severity of NAS is decreased in
preterm neonates (Kocherlakota 550). Kocherlakota explains this can be because of decreased
exposure, transmission and morphine clearance (550). Withdrawal symptoms vary across
neonates depending on the type of opiate their mother was taking. Importantly, no relationship
has yet been found between maternal opioid dosage and NAS (Kocherlakota 549). While this is
an important piece of evidence for incorporating mothers into NAS treatment, the limited
knowledge surrounding the pathophysiology of NAS makes it difficult to predict long-term
developmental deficits in these infants.
Although little knowledge exists surrounding long-term effects of NAS on
neurodevelopment, some evidence supports that infants born diagnosed with NAS are at
increased risk for deficiencies with cognitive, language and visual-motor skills. Neonatologist
Stephanie Merhar’s retrospective review on neurodevelopmental outcomes in infants treated for
NAS found that in comparison to the normative population, children with NAS are at risk for
lower developmental scores at 2 years of age (Merhar 590). These lower scores were still within
the normal range in most cases; however, the research team considered a 4-6-point difference as
clinically significant (Merhar 590). This study also reported that 7 of their 87 two-year-olds (8%)
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needed treatment for strabismus, or lazy eye, by age three (Merhar 591). While the risk for longterm developmental effects is nothing like the outcomes of fetal alcohol syndrome, such as a
high risk of mental retardation and significant developmental delays, the evidence of long-term
developmental deficiencies supports the need for early intervention in families (Tribble, “For
Babies Of The Opioid Crisis, Best Care May Be Mom's Recovery”).
Another study examining the neurodevelopment of infants with NAS at six months adds to
Merhar’s conclusion with evidence that “infants born to methadone-maintained opioiddependent mothers had lower developmental scores in all areas compared to infants matched for
gestation, birth weight, and postcode at delivery” (McGlone and Mactier 20). McGlone and
Mactier report that 32 of their cohort of 81 (40%) drug-exposed infants who returned for follow
up failed a visual assessment at six months (20). In some areas, there is strong evidence to
suggest an increased focus on the treatment of NAS and follow up. Director of the Pediatrics
Center for Addiction and Pregnancy at Johns Hopkins, Dr. Lauren Jansson, comments on the
effects NAS: “The one solid thing we can say about children who are exposed to substances
prenatally is that their mothers need treatment” (qtd in Tribble, “For Babies Of The Opioid
Crisis, Best Care May Be Mom's Recovery”). The treatment of NAS cannot be successful
without the incorporation of the mother.
In addition to mental and physical health risks, infants with NAS spend more time in the
hospital, which in 2012 resulted in $1.5 billion excess costs (Falletta 126). Furthermore, a 2018
study analyzing neurodevelopmental outcomes in infants treated for NAS reported that the
average hospital charges for infants with NAS amount to more than five times the cost for
healthy infants (Merhar 587). To provide an example, the rising number of infants born with
NAS in 2000 in Indiana resulted in treatment costs of $190 million, compared to an almost
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fourfold increase of $720 million in 2009 (Box, “Where Indiana Stands: NAS and the Opioid
Epidemic). Pharmacological care is a significant factor that persists hospital stays for infants
with NAS, whether in regard to the administration of medical intervention or with delays in
doing so. Nonpharmacological care is associated with the most advantages for decreasing
hospital stays, such as the encouragement of breastfeeding and overall supportive care
(Kocherlakota 553, 555). NAS is a risky and complex condition for babies, mothers, and their
families that also comes with social, economic and health care costs for society (Kocherlakota
549).
In order to develop the most successful treatment programs for women of childbearing age
and infants with NAS, it is important to understand what societal factors contributed to the
devastation of this epidemic. In order to move forward, the nation must first understand and learn
from previous mistakes in order to develop preventative and effective treatment models.
Good Intentions Gone Wrong: How Managing Pain Lead to a Crisis and Other Root
Causes of the Opioid Epidemic
Substance use disorders have increasingly worsened throughout the nation because some
addictions have stemmed from doctor-prescribed medications. In 2015, Indiana providers wrote
109.1 opioid prescriptions per 100 people, which totaled to approximately 5.8 million
prescriptions (National Institute on Drug Abuse, “Indiana Opioid Summary”). Travis Rieder, a
bioethics research scholar, shares his story of opioid addiction after a serious motorcycle
accident. Rieder describes his fourth week of opioid withdrawal: “As my brain experienced life
without prescription opioids for the first time in months, I thought I would die. I assumed I
would die” (Rieder, “The Agony of Opioid Withdrawal - and What Doctors Should Tell Patients
about It”). The problem was created when Rieder was never properly weaned off of his
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medications. Tragically, he found himself battling suicidal thoughts due to long-term mistakes in
his medical care. Rieder mentions he was even turned away from a rehabilitation facility (“The
Agony of Opioid Withdrawal”). The physician who prescribed him oxycodone ordered an
aggressive tapering regimen and advised Rieder to go back on the medication when he was
suffering immensely from withdrawal. “‘My initial advice to you is clearly bad,’” the doctor
admits when Rieder and his wife frantically ask for anything that can help them (“The Agony of
Opioid Withdrawal”). There are deeply-rooted problems that need to be addressed when it comes
to defeating the opioid epidemic. Drug companies and the economy have been two largely
influential factors in the growth of the complex web of the opioid epidemic.
In the early 1990s in the United States, concern about undertreating pain led to increased
emphasis on pain management and treatment (Krans and Patrick, “Opioid Use Disorder in
Pregnancy”). Along with blood pressure, respiratory rate, temperature, and heart rate, pain is a
symptom reported in over 80% of physician visits and costs the American public over $100
billion each year (Walid 417). Therefore, the American Pain Society introduced pain as the “fifth
vital sign,” improving recognition of pain’s importance in patient outcomes (Krans and Patrick,
“Opioid Use Disorder in Pregnancy”). Physicians remained committed to holistic treatments of
their patients and prescribed what the drug companies produced – highly effective pain
management medications. The addictive danger of these drugs has exacerbated the country’s
opioid crisis.
Today, drug companies such as Purdue Pharma, Johnson & Johnson and CVS are facing
lawsuits as more evidence surfaces surrounding their inaccurate marketing of prescription drugs
to the public. At the center of the criticism is Purdue Pharma, a private company based in
Stamford, Connecticut. The prescribing of opioids began exploding in 1996 when Purdue
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Pharma launched a campaign misinforming the medical community about the risks of opioids
(Keefe, “The Family that Built an Empire of Pain”). OxyContin was developed by Purdue and
released in 1995 as a medical breakthrough (Keefe, “The Family that Built an Empire of Pain”).
There is evidence that Purdue Pharma funded doctors and researchers to persuade the public that
opioid addiction was an exaggeration and that their drug, OxyContin, could safely treat a number
of different pain problems. Other organizations like Johnson & Johnson also pushed unscientific
theories about drug addiction, supposedly in order for doctors to prescribe more opioids after
signs of dependency showed in patients (Mann, “Opioid Litigation Brings Company Secrets Into
The Public Eye”). Even employees of the FDA were targeted.
In 1995 the FDA approved a package insert for OxyContin with the information that the drug
was indeed safer than competing painkillers (Keefe, “The Family that Built an Empire of Pain”).
Within two years, the FDA examiner who oversaw the process had left and accepted a job at
Purdue Pharma (Keefe, “The Family that Built an Empire of Pain”). Now it is known that even
before the release of OxyContin, through focus groups Purdue learned the risks of the “abuse
potential” of opioids (Keefe, “The Family that Built an Empire of Pain”). In the face of losing
billions of dollars in lawsuits today, “Purdue executives acknowledged that their prescription
opioids are far more addictive and dangerous than the company was telling doctors (Mann,
“Opioid Litigation Brings Company Secrets Into The Public Eye”). Profit in the economic sector
has clearly been a driving force in the severity of the nation’s opioid epidemic.
The opioid epidemic has infiltrated all 50 states in the nation and has reached people of all
genders, race and class. There have been attempts to reduce the number of deaths from overdose,
such as needle exchange services and harm reduction programs. But, a “one size fits all”
treatment plan would certainly not be equipped to cover all facets that the opioid epidemic
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touches. This is especially true for women of childbearing age. Their treatment plans must
encompass the women as individuals along with their neonates and other children. The gaps that
need to be filled to overcome the opioid crisis, such as access to care, education of health care
personnel, and community support, must also be unique in the treatment of women of
reproductive age. Pregnancy within the opioid epidemic is a unique and important area of the
crisis that requires change and intense research for imperative improvement.
Systematic Factors Perpetuating the Crisis and Preventing Recovery
There are many barriers to treatment for pregnant women and mothers with opioid use
disorder. The societal stigma that accompanies OUD during pregnancy and motherhood, such as
fear of child protective services and imprisonment, negatively influence women not to seek
essential prenatal and postpartum care (Johnson and Campopiano 2). Misinformation and lack of
knowledge in training of health care professionals in providing care for struggling women are
also significant barriers (Johnson and Campopiano 2). Legal consequences can play a large role
in these scenarios. Several states have statutes that sanction against pregnant women with OUD
(Krans and Patrick, “Opioid Use Disorder in Pregnancy”). While the goal of these efforts is to
protect the infant from opioid exposure, in reality they drive women away from seeking care,
continuing to engage in care, or limit them to the availability of care (Krans and Patrick, “Opioid
Use Disorder in Pregnancy”).
Accessibility
One of the core problems for women of reproductive age seeking treatment for an opioid
use disorder is lack of accessibility. Imagine the life of someone like 25-year-old Amanda
Hensley who battled opioid addiction during her second pregnancy. She shares her isolated
struggle: “‘Either I was puking from morning sickness or I was puking from being high. That’s
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kind of how I was able to hide it for a while,’” NPR reports (Tribble, “Pregnant and Addicted:
The Tough Road to Family Health”). With the goal of getting clean, yet without the resources to
do so, Hensley sought help following separation from both her mother and her baby’s father.
After being rejected from two hospitals and several clinics, Hensley only received medical
attention when she went into withdrawal and was sent to the emergency room (Tribble,
“Pregnant and Addicted: The Tough Road to Family Health”). Upon finally receiving medicallyassisted care from this hospital, both she and her baby safely tapered off of opioids.
Despite MAT being the accepted standard of care for opioid dependence treatment in
pregnant women, and its crucial role in both the mother’s and infant’s recoveries, there are
several important barriers to this treatment method. Although very difficult to regulate,
methadone maintenance has been favored over buprenorphine because of the potential to provide
access to other behavioral therapies. It has been argued that because methadone is typically
dispensed from a licensed opioid treatment program, patients are more likely to participate in
comprehensive treatment by attending the clinic daily (Hand 224). In contrast, buprenorphine is
typically prescribed by a physician in a primary care setting requiring refill after 30 days, which
may drastically reduce the element of human contact and clinic check-in (Hand 224). Access to
methadone clinics, however, depends largely on geography, transportation and employment. For
example, the creation of methadone clinics has been rejected by communities out of fear of
bringing crime to those neighborhoods. Lack of transportation, sick leave, daycare and time for
travel are major deterrents to visiting a methadone clinic. Furthermore, methadone maintenance
therapy (MMT) has also come under scrutiny because many patients are in need of more
intensive, residential services that explicitly decline MMT patients (Hettema and Sorensen 468).
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Because of pharmacological and societal factors, buprenorphine has become the preferred
treatment medication for pregnant women.
Another misconception that argues in favor of methadone over buprenorphine raises a
concern around insurance coverage. Methadone is incorrectly believed to be more readily
available than buprenorphine. Medicaid is known to cover methadone in most states, while only
private insurance has covered buprenorphine in the past (Hand 224). However, one 2016 study
reports that Medicaid covers methadone maintenance therapy (MMT) in only 29 states, because
it is not covered in most states with a law that permits child abuse charges for illicit drug use in
pregnancy (Angelotta 598). In contrast, the recent expansion of Medicaid eligibility improved
access to opioid use disorder treatment with a significant increase in buprenorphine and naloxone
prescriptions (Saloner 1). The advantages of buprenorphine, including lower severity of NAS
and lower levels of physical dependence, have encouraged treatment standards to shift towards
increasing the availability of buprenorphine in addiction recovery treatment. Because Medicaid
can differ state by state, insurance remains a complex and important element to consider with
access to care regarding this national epidemic. Accessibility is one of the first steps in
considering treatment reach to patients, but adherence is a critical measure to consider in the
success of programs offered.
Adherence
The World Health Organization defines adheres as “the extent to which a person’s
behavior – taking medication, following a diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a health care provider” (World Health Organization 17).
Research has focused on adherence to medication specifically in the past, but the WHO has
worked towards a more holistic and encompassing definition of adherence in terms of treatment.
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Importantly, accurate assessments of adherence behavior are crucial not only to determine the
success of treatment programs, but in order to evaluate the efficacy of treatment. As with many
other areas of addiction treatment, there is no “gold standard” for measuring adherence behavior
(World Health Organization 18). The WHO recognizes that while adherence measurement
provides useful information that outcome evaluations alone cannot provide, adherence is only an
estimate of the true behavior of a patient (World Health Organization 19). No single
measurement strategy has been deemed the “gold standard,” and adherence is just one facet of
program evaluation that can contribute to determining success. Moreover, adherence in regard to
addiction treatment cannot be considered in black and white, for example, remaining abstinent
from drugs cannot be a singular positive outcome and relapse cannot be measured only as a
negative outcome. Adherence has to be calculated based on the treatment program or research
study, program goals, available resources, the response burden on the patient and how the results
will be used (World Health Organization 19). Adherence must be discussed with an awareness of
its complex definition and without it being the center of success in evaluation of treatment
programs.
Furthermore, it is crucial to analyze the timeline of medication treatment intervention.
Medicaid may cover methadone and/or buprenorphine, but several studies have suggested that
early treatment intervention is key for successful retention rates. Many women are only able to
enroll in treatment once they become pregnant because of program availability and/or insurance
coverage (O’Connor 27). Family medicine practitioner Alane B. O’Connor led a study
examining the rates of treatment retention at 6 and 12 months postpartum of women in
medication treatment using buprenorphine during pregnancy (O’Connor 26). The authors of this
study suggested that early treatment access would improve treatment outcomes (O’Connor 28).
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Early treatment was defined as either being in treatment at the time of conception or entering
medication treatment prior to 13 weeks’ gestation (O’Connor 26). The association between early
treatment intervention and successful retention rates emphasizes the importance of expanding
access of medication treatment to women of childbearing age, not just pregnant women, with
opioid use disorders (O’Connor 28).
Similarly, a separate study led by perinatal psychiatrist Jessica L. Coker, retrospectively
examined pregnant women with OUD treated with buprenorphine and evaluated them as
adherent, moderately adherent, and nonadherent (Coker 146). This study observes that treatment
adherence is essential (Coker 146). Because the findings of this study included that adherence
during pregnancy was influenced by the severity of withdrawal symptoms and clinical response,
the authors suggested that “more aggressive buprenorphine dosing strategies early in treatment
targeting rapid control of withdrawal symptoms may enhance adherence through delivery”
(Coker 147). In the use of buprenorphine, early treatment access and maintained adherence
through delivery are two crucial elements of MAT that need to be addressed with pregnant
women. Restrictive insurance coverage, access to clinics, transportation, employment and/or
education, and programs offering MAT are all significant structural obstructive factors for
women of reproductive age seeking medically-assisted care. The stigma society holds towards
pregnant women and mothers who use drug users are negative attitudes interwoven within
institutions, making it very difficult to overcome and change.
Stigma
The language that exists around substance use disorders continues to paint the picture that
people who suffer from these disorders are poor, irresponsible “junkies” who have chosen their
fate. A quote from Ohio Sheriff Walter Bender explains: “Opioids reach every part of society:
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blue collar, white collar, everybody. It’s nonstop. It’s every day. And it doesn’t seem like it’s
getting any better” (Nachtwey and Moakley, “See Inside the Worst Opioid Addiction Crisis in
U.S. History”). It is incorrect and unjust to label people plagued by the opioid epidemic as
“junkies.” Sons and daughters, friends and coworkers are all at risk of developing substance use
disorders. Just like Madelyn Ellen Linsenmeir’s story, even though her addiction affected the
way she lived, it did not define her (Bowman, “The Viral Obituary Of An Opioid Addict: 'She's
Just One Face' Of The Epidemic”). Society places immense personal responsibility on addicted
individuals, especially pregnant women. The reality is that addiction is not a moral problem but a
medical problem that cannot be beaten alone.
Addiction is stigmatized in American society because it is inherently linked to self-worth.
Semi-religious, character re-building 12-step programs were created in 1935, almost a century
ago, as the only alternative other than jails or death for people with SUDs. These programs
influenced society to respond to addiction in such negative ways. The language used around
addiction still today, especially in the media, perpetuates negative attitudes towards addiction.
Society paints the picture of an addict as “disposable” and “deserving of ridicule” (Flanagin,
“The Surprising Failures of 12 Steps”). The medical field could be considered as one of the most
progressive areas in regard to addiction with more treatment proposals and programs offering
services that treat addiction as a chronic disease. However, according to Alcoholics Anonymous
(AA), in 2017 over 2 million people were individual and group members worldwide (“Estimates
Worldwide A.A. Individual and Group Membership”). Despite the minimal success and retention
rates of the 12-step programs, 31% success at best and overall 5% retention rate (Flanagin, “The
Surprising Failures of 12 Steps” and Glaser, “The Irrationality of Alcoholics Anonymous”), AA
is still one of the most popular treatment programs for people struggling with addiction. America
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believes the best solution is to never engage with the addictive substance again. While 12-step
programs can be successful for some people, the overall program is not holistic and does not
focus on treating addiction as another facet of health, such as a chronic disease like diabetes. The
religious values behind AA and the non-medical treatment practices are significant examples of
how negative attitudes of addiction are persisted as a moral problem rather than a physiological
disease.
Medical treatment for SUDs, such as methadone maintenance, is also associated with the
stigma of addiction being a moral choice rather than an incurable chronic disease. It is not widely
understood that methadone is a medically safe treatment medication with minimal side effects
(Lowinson 619). Methadone is misunderstood and misperceived as substituting one addiction for
another (Lowinson 629). This stigma is reflected in lack of funding, community opposition, and
the undertreatment or no treatment of pain if patients are hospitalized for surgery (Lowinson
629). Furthermore, a study examining treatment retention in pregnant women prescribed
buprenorphine, reported that as of 2017 96% of states have opioid dependence rates higher than
their buprenorphine treatment capacity rates (O’Connor 27). Although many scientific studies
provide evidence for the efficacy and safety of buprenorphine during pregnancy, the gap between
treatment need and availability overwhelmingly remains. This stigma and inability to access care
negatively affects the self-esteem of patients (Lowinson 629). The approval of buprenorphine as
addiction medication has partially assisted in stigma reduction and increased accessibility;
however, the nation still has a long way to go for the inclusion of pregnant women with OUD
and their progression of successful treatment.
The gap between treatment demand and accessibility perpetuated by stigma can be
attributed to America’s historical Prohibitionist Model. The Prohibitionist Model has been
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valued in American society as exemplified through the ban on alcohol throughout the 1920s and
current war on drugs. However, there has been an international movement of recognizing the
failure of the Prohibitionist Model and shifting towards more regulatory and reformative models.
This is significant global progress. Failure of the Prohibitionist Model has become evident
through the understanding that “drug prohibition is the dominant driver behind the creation of
a[n] illegal market that spawns significant health and social pathologies, harmfully engages our
youth, and makes impure illegal drugs widely available” (Haden 1). Making a substance illegal
makes it more desirable, cheaper on the black market, and readily available in highly dangerous
and potent forms. Moreover, the goals of prohibition directly oppose the goals of treatment and
prevention (Haden 4). Reasons for this are that “Prohibition impairs the development of honest,
factual prevention programs and prohibition marginalizes, and alienates drug users” (Haden 4).
The Prohibitionist Model is directly tied to stigma. This model fuels negative attitudes towards
people who break the law and use illegal substances, as well as bolsters the incorrect belief that
addiction is a choice. People are less likely to come forward about their drug addictions and seek
help because of the risk of criminal punishment.
Dr. Daniel Ciccarone, an ethnographic researcher and Professor of Family and
Community Medicine at University of California, San Francisco Medical Center, and a dedicated
fighter of the opioid epidemic, describes how the Prohibitionist Model only adds to the problem
at the local level (Brown, “The Opioid Crisis is Driven by Prohibition”). Ciccarone comments
that on top of the failure of prohibition on the international scale, prohibition also stigmatizes the
individual and the population, with only “dysfunction” created because of this (Brown, “The
Opioid Crisis is Driven by Prohibition”). Essentially on all levels, prohibition has failed. In order
to overcome stigma and provide realistic and successful drug-regulating models that will reduce
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the opioid epidemic rather than fuel it, America needs to progress beyond the Prohibitionist
Model.
According to a study conducted by Lynn Falletta, the fear of child protective services
(CPS) acts as a barrier to care for pregnant women battling addiction, with stigma in the
community about CPS contributing to this. For example, Falletta suggests that “community
outreach ought to provide education about the role of CPS, including helping parents understand
that they may seek help for substance use issues without their children necessarily being
removed from their care” (132). The stigma that exists within societies of CPS being an unjust
organization that removes children from their parents is difficult to overcome, especially with
women who are engaging in illegal activities. The current protocol is that in all states, health care
workers are required to notify CPS when an infant has been identified as exposed to illicit
substances in utero (Angelotta 596). Simply delivering a baby at a hospital is a risk for a
pregnant woman battling addiction. Regrettably, it is estimated that up to 79% of foster care
placements are the result of parental substance abuse (Falletta 126). Between 2013 and 2014, at
the same time the opioid epidemic was rising, there was a 3.5% increase in children in foster
care, amounting to a reported total of 415,129 children in the system (Falletta 125). Moreover, in
2015, the number of children in foster care was 428,000, the highest since 2008 (Falletta 125).
There is a distinct tie between the involvement of CPS and the consequences of addition. While
some CPS cases are positive and turn out to be successful for some women, there is a grounded
societal problem with stigma surrounding CPS and treatment accessibility for women with
SUDs. Better education about the process of CPS and less harsh legal punishments against
individuals battling addiction would improve access to and retention of treatment.
Legal Barriers
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The legal ramifications that surround drug use during pregnancy are not to be
underestimated. Many jurisdictions have established rigid punishments for nonviolent drug
offenses, including mandatory incarceration (Crowley 1). The criminal justice system, however,
fails to utilize medical judgment in the treatment of opioid use disorders (Olsen and Sharfstein,
“Confronting the Stigma of Opioid Use Disorder – and Its Treatment”). Inmates are often not
allotted the benefit of continuing medication-assisted treatment while incarcerated and restricted
from methadone or buprenorphine. If these prisoners suffered from diabetes or other physical
health conditions, however, they would still be allowed to take prescription drugs such as insulin
(Olsen and Sharfstein, “Confronting the Stigma of Opioid Use Disorder – and Its Treatment”).
Without opioids or the assistance of medications to taper off of the drugs, inmates face an
extremely high risk for overdose if relapse occurs either in prison or following release (Olsen
and Sharfstein, “Confronting the Stigma of Opioid Use Disorder – and Its Treatment”). Pregnant
women face similar health consequences because of legal sanctions, with the added stress of
having to abandon their families if sentenced to prison, or the high possibility of losing rights to
their children because of their addiction. Obstacles such as these prevent progress towards
reducing and eliminating the burden of the opioid crisis.
For example, in 2014, Tennessee passed a new law that criminalized substance use
during pregnancy. This act was made with good intentions in an effort to reduce neonatal
abstinence syndrome and maternal opioid use (Angelotta 596). However, the law resulted in a
woman from Tennessee being charged with criminal assault if her infant was born addicted to or
harmed by narcotic drug use during pregnancy (Angelotta 596). The state medical association
opposed this new sanction, leading to its expiration in summer of 2016 (Angelotta 596).
Although Tennessee has been the only state to explicitly make substance use during pregnancy
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criminal child abuse, 18 other states put pregnant women who use narcotics at risk for civil child
abuse charges (Angelotta 596 and Miranda, “How States Handle Drug Use during Pregnancy”).
Charges include child endangerment, providing a minor with illicit substances via the umbilical
cord, and manslaughter (Angelotta 596). Furthermore, in all states health care professionals are
required to notify child protective services (CPS) when an infant is diagnosed with NAS
(Angelotta 596). Combined with the devastating legal consequences and potential for a mother to
have her child taken away from her, women are continuously deterred from seeking the crucial
prenatal and postpartum care for themselves and their babies.
The legal battle for pregnant women battling addiction is certainly not over. In April of
2018, Pennsylvania’s court system was in the midst of battling child abuse concerns with a
pregnant woman who tested positive for marijuana and suboxone, the preferred drug used with
MAT, at the time of delivery (Scolforo, “Court to Decide if Drug Use while Pregnant is Child
Abuse”). The infant was reportedly in the hospital for 19 days being treated for severe
withdrawal symptoms. While many states have moved towards a more reformative approach to
pregnant women who use drugs, it is alarming that this question is still being grappled with in the
legal system. A Superior Court judge on the case, Geoffrey Moulton, expressed his opinion on
the situation that substance abuse during pregnancy “‘may constitute child abuse’ if child welfare
authorities can prove she ‘intentionally, knowingly, or recklessly caused, or created a reasonable
likelihood of, bodily injury to a child after birth’” (Scolforo, “Court to Decide if Drug Use while
Pregnant is Child Abuse”). Unfortunately, many influential and powerful leaders in society still
hold Moulton’s position. The interests of the child are undeniably one of the most important
things at the top of policy makers’ and health professionals’ lists, however expansion of
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treatment programs need to be taking up headlines rather than continued debates on child abuse
laws.
One of the biggest issues surrounding the opioid crisis is that policy makers are years
behind in their progress of adequately addressing the legal needs of the epidemic. Dr. Ciccarone
comments that policy makers are four to eight years behind in the battle of the opioid epidemic
(Brown, “The Opioid Crisis is Driven by Prohibition”). Dr. Ciccarone explains how policies are
still attempting to attack the pill crisis of the opioid epidemic, or the prescription crisis, instead of
focusing on what is happening right now with differentiating drugs on the street. When talking
about a highly toxic and dangerous opioid, fentanyl, Ciccarone emphasizes:
We don’t need to just address prescribing and exuberant prescribing practices of
physicians, we need to understand fentanyl is a poison…we have to stop waiting for the
bodies to pile up, and toxicological reports which are telling us what’s happening in
people who have died, I want to know what’s happening in people who are living.
(Brown, “The Opioid Crisis is Driven by Prohibition”)
Dr. Ciccarone is very passionate and driven about what legal changes not only need to be made,
but how they could work in America. Ciccarone takes a stance away from blaming doctors and
big pharma for over-prescribing, but instead investigating the root of the problem, like chronic
pain. Attacking the problem at its core works at addressing real-time concerns of the opioid
epidemic rather than analyzing retrospective results of “outdated data,” as Ciccarone makes
reference to (Brown, “The Opioid Crisis is Driven by Prohibition”). The U.S. needs to put its
efforts toward less restrictive policies.
Ciccarone is against the Prohibitionist Model, and advocates for a “decriminalization
model,” otherwise known as the Portuguese Model or drug policy in Portugal. Ciccarone
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explains that the Portuguese Model does not charge for possession for drugs, but instead focuses
on especially those at risk for developing, or who have developed, a use disorder and connecting
them with proper resources for treatment (Brown, “The Opioid Crisis is Driven by Prohibition”).
Ciccarone succinctly states that what the country needs is the vision that follows through with
the sentiment, “We’re going to take care of you and we’re going to help you get through this”
(Brown, “The Opioid Crisis is Driven by Prohibition”). A model of this type is especially crucial
for pregnant women in America. Although it currently seems like the U.S. has a long way to go
in altering laws and expanding treatment in order to accept addiction as a chronic disease, there
are other countries like Europe and Canada that can act as models. Changing policies is not the
only act that is going to work towards reducing the opioid epidemic, a change in mindset and a
normalization of addiction as a chronic disease, like diabetes or cancer, is the ultimate
progression that is going to produce rational and effective results.
Opioid Use Disorder Treatment
In 2014, it was reported that 22.5 million people in the United States needed treatment for
an illicit drug or alcohol use disorder, but only 4.05 million, or 18%, received any treatment
(Crowley 1). This statistic is far below treatment rates for other chronic diseases such as
hypertension, diabetes, or major depression, which all had treatment reports over 70% (Crowley
1). The first point of contact for women seeking help for opioid dependence is considered a
crucial window and step in their treatment process. Many women become discouraged and stop
seeking treatment, meaning they never receive the proper care they and their babies need.
Current available treatment options for OUD include pharmacotherapy, or medication-assisted
treatment (MAT), abstinence, harm reduction, comprehensive approaches that include
coordinated care and women-centered services, and the peer model. While MAT is the current
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standard of care for opioid dependent women, it is only one of the important elements of
coordinated care that pregnant women need to diminish their and their babies’ addictions. MAT
has evolved in order to meet the needs of mom and baby over recent years and is an initial
gateway into long-term addiction treatment for women of childbearing age.
Pharmacotherapy
All individuals with an opioid-use disorder will require some form of medication
management as part of their treatment (Hand 223). Medication-assisted treatment, or MAT, is the
use of Food and Drug Administration (FDA)-approved medications in combination with
counseling and behavioral therapies. MAT can be described as the gold standard of
pharmacotherapy for OUD and is the most common form of medication assistance. A medicallymonitored switch from opioid use to opioid maintenance therapy has several advantages, such as
the decrease of maternal and neonatal morbidity because of a stable opioid dosing regimen, a
minimized risk for the experience of withdrawal, a reduction in risk-taking behavior, a decrease
in the spread of hepatitis and HIV, and an improvement in the connection and utilization of
health care services (Krans 372). The overarching goal of MAT is to provide a “whole-patient”
approach to the treatment of substance use disorders [SAMHSA, “Medication-Assisted
Treatment (MAT)”]. MAT is now the current standard of care for substance abuse during
pregnancy, supported by the World Health Organization, the American Society of Addiction, and
the American College of Obstetrics and Gynecology (Angelotta 595). Buprenorphine and
methadone are both long-acting opioid medications used in MAT.
Although methadone has been used for the last 40 years in treating opioid dependence,
buprenorphine was approved by the FDA in 2002 for its lower probability of overdose and
evidence of lower levels of physical dependence (Older, “Buprenorphine Treatment in
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Pregnancy: Less Distress to Babies”). Buprenorphine is an opioid partial agonist with beneficial
pharmacological properties such as its ability to lower potential for misuse; the diminishment of
the effects of physical dependency to opioids, such as symptoms and cravings; and the increased
safety in case of overdoses (SAMHSA, “Buprenorphine”). A partial agonist means that, similar
to opioids, buprenorphine produces comparable effects such as euphoria or respiratory
depression (SAMHSA, “Buprenorphine”). However, the effects of buprenorphine are weaker
than a full opioid agonist such as heroin. Buprenorphine has a “ceiling effect” (SAMHSA,
“Buprenorphine”), meaning that buprenorphine’s effects increase with each dose until they level
off at moderate doses, even if the dosage increases from that point on (SAMHSA,
“Buprenorphine”). In simple words, there is a certain point where the effects of buprenorphine
peak and do not get any stronger. In turn, buprenorphine lowers the risk of misuses, dependency,
and side effects, and, because buprenorphine is a long-acting agent, patients may not have to take
it every day (SAMHSA, “Buprenorphine”). Buprenorphine does come, however, with the
potential for side effects including many of the symptoms of withdrawal, such as nausea,
vomiting, constipation, muscle aches and cramps, cravings, sleep disturbances, distress,
irritability and fever (SAMHSA, “Buprenorphine”). Importantly, evidence shows that
buprenorphine is superior to methadone in reducing withdrawal symptoms in newborns (Older,
“Buprenorphine Treatment in Pregnancy: Less Distress to Babies”).
Methadone historically has been the “gold standard” MAT drug of choice for pregnant
women mainly because it is safe and effective when taken as prescribed (Saia 255; SAMHSA,
“Methadone”). Methadone changes how the brain and nervous system respond to pain
(SAMHSA, “Methadone”). The painful symptoms of opioid withdrawal are reduced, and the
euphoric effects of the drugs are blocked (SAMHSA, “Methadone”). Methadone comes in
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several different forms, such as pills, liquid, and water, and must be taken once a day
(SAMHSA, “Methadone”). Methadone has been proven to be effective in higher doses
(SAMHSA, “Methadone”). Importantly, methadone can be addictive (SAMHSA, “Methadone”).
For reasons such as these and methadone’s high association with NAS, buprenorphine has
become the preferred MAT drug for pregnant women (Older, “Buprenorphine Treatment in
Pregnancy: Less Distress to Babies”).
A recent research project, The Maternal Opioid Treatment: Human Experimental
Research (MOTHER), was one of the first studies that prospectively followed pregnant women
with OUD from enrollment until at least 28 days after giving birth (Older, “Buprenorphine
Treatment in Pregnancy: Less Distress to Babies”). The researchers of this study were able to
closely examine the severity of NAS following prenatal exposure to methadone or buprenorphine
(Older, “Buprenorphine Treatment in Pregnancy: Less Distress to Babies”). Because the women
of this study reported use of heroin or prescription painkillers with low rates of other illicit drug
use, NAS could be clearly related to the opioids (“Buprenorphine Treatment in Pregnancy: Less
Distress to Babies”). The MOTHER study identified a medication, buprenorphine, that reduces
withdrawal distress to newborns, and ways to release infants from the hospital sooner (Older,
“Buprenorphine Treatment in Pregnancy: Less Distress to Babies”). MOTHER was a doubleblind, double-dummy, randomized, stratified, parallel group-controlled trial which took place at
eight different sites internationally and included 131 mothers and their newborns (Jones 29).
Ultimately, buprenorphine is safer and superior to methadone and can be prescribed to pregnant
women with OUD by a certified physician. The process of how to taper postpartum women off
of partial opioid agonist medication is an additional area of importance.
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Unfortunately, there is no gold standard for duration of tapering off of addiction
medication. Specific individuals are likely to respond to tapering regimens differently, therefore
the time spent taking buprenorphine or methadone should be analyzed and determined by a
physician and their patient. In regard to buprenorphine, evidence has shown that a gradual taper
off of the medication is the safest and most successful way to prevent relapse and withdrawal
(Women’s College Hospital 4). A general rule of thumb has been regarded as the longer a patient
was addicted to opioids, the longer they should stay on buprenorphine (Women’s College
Hospital 4). Interestingly, one randomized study examining the tapering schedule of
buprenorphine amongst the general population with participants aged 15 years and older, found
that there was no advantage in prolonging the duration of taper when comparing groups at 7 and
28 days (Ling 256). This data is important when considering cost-effectiveness and insurance
coverage. Tapering regimens specific and individualized to pregnant and postpartum women also
require independent gold standards from the rest of the population battling OUD.
Pregnant women participating in MAT should continue methadone or buprenorphine
maintenance during labor and delivery (Krans 374). MAT during pregnancy and following
delivery is critical because pregnancy-specific dosing recommendations result in a significantly
greater mean buprenorphine dose at the time of delivery (Krans 5). Drug metabolism is
significantly altered in pregnancy because of the physiologic changes necessary to support the
fetus (Krans 5). There is a need to increase the dose of buprenorphine as well as the frequency of
dosing compared to nonpregnant patients (Krans 5). Additional doses of short-acting opioids
could be needed for women who undergo cesarean sections, for example, in addition to MAT
(Krans 374). A study evaluating women with OUD reported a 70% increase in opiate analgesics
following C-sections for women maintained on methadone and a 47% increase for women on
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buprenorphine maintenance therapy (Krans 375). Postpartum women require close monitoring in
regard to MAT because doses required during pregnancy could exceed requirements after
delivery. (Krans 375). Consequently, tapering regimens must reflect this.
In comparison, similar advice has been given regarding methadone tapering. Individual
patients may have differing responses to their prescribed tapering regimen, in partnership with
emotional fears about developing withdrawal and eliminating their opioids in general (Kral 4).
Ultimately, unless there is a pressing need for a rapid taper, a slower taper is tolerated much
better and is safer (Kral 3). Because withdrawal is highly discouraged for pregnant women, a
gradual taper would reduce the risk of this and help prevent relapse during the postpartum
period. Opioid withdrawal is associated with an increased risk of spontaneous abortion, preterm
labor, fetal distress and continued illicit drug use (Krans 372). A study evaluating 95 women
who elected inpatient opioid detoxification during pregnancy reported that 42, or 44%, relapsed
and used illicit drugs before delivery (Krans 372). Yet, income level, insurance coverage,
occupation, access to care, and other barriers to treatment are important to consider in suggesting
a preferred method of pharmacotherapy treatment.
In conclusion, even with the established efficacy of MAT, it is important to remember it
is only one facet of a multivariable treatment formula. For example, MOTHER, beginning only
about 15 years ago was one of the first studies following opioid-dependent pregnant women from
enrollment until at least 28 days after giving birth (Jones 248). As this study, which began in
2005, was essentially the first of its kind, only recently has the health care community has
officially examined medication-assisted treatment as an ethical and viable option for pregnant
women with OUD. MOTHER was designed to gain experience with the use of buprenorphine
during pregnancy, and ultimately provided evidence of its safety and advantages for pregnant
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women and their fetuses. Moreover, the timeline of this study affirms that there has been a short
period for the development of alternative and additional ways to treat addiction other than MAT.
Despite the recent emergence of discussions and research dedicated to opioid addiction treatment
for pregnant women, barriers such as the vast exclusion of pregnant women from
pharmacological and preventive trials (Blehar 40), the stigma associated with drug use during
pregnancy, and the lack of an acceptance of addiction as a disease continue to act as deterrents
for long-term, successful treatment options for women of childbearing age.
Abstinence
Abstinence has been the most popular and widely accepted treatment for substance use
disorders in the research and medical fields until relatively recently. Programs that assist with
maintaining abstinence were created alongside the debate of addiction being a moral or medical
problem, although society has made large leaps towards assessing and treating addiction as a
chronic disease today. Alcoholics Anonymous (AA), Narcotics Anonymous (NA), Cocaine
Anonymous (CA), Crystal Meth Anonymous (CMA), Heroin Anonymous (HA), and others are
12-step programs designed for drug users in general or specific addictions. 12-step programs
were once recognized as the only viable treatment options for people battling addiction, and still
are commonly recommended and utilized today, according to the American Addiction Centers.
However, there have been many critiques against the program’s success and feasibility. The 12
Steps were designed to maintain abstinence on a largely individual level, operating as a “one size
fits all” model. The program’s largely personal commitment and the religious influences
associated with the 12 steps have been the biggest criticisms against the model. Because AA was
created parallel to Christian values, its religious and spiritual affiliation has remained present in
the goals of the organization.
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Following the 12-step model will yield mental and emotional transformative practices
and tools (Thomas, “12 Step Drug Rehab and Alcohol Treatment Programs”). A few examples of
goals of the 12 steps are as follows:
•

The ability to recognize and admit that one is experiencing an addiction problem

•

Self-observation and awareness of the behaviors that were part of and arose from the
addiction, as well as those that help promote self-restraint

•

A chance to practice that restraint and build self-esteem in one’s positive capabilities
(Thomas, “12 Step Drug Rehab and Alcohol Treatment Programs”)

The 12 Steps have a large focus on the individual self and process of spiritual awakening.
Although there are 12 main base steps outlined in the original Big Book of AA, different groups
have altered and adapted them to fit unique needs. Since 12 step programs are anonymous and
because AA is the main publisher of its results, it is difficult to determine an accurate success
rate. However, the American Addiction Centers reports that 40% of attendees drop out within the
first year (Wagener, “What is the Success Rate of AA?”). Because the 12 Steps are centered on
maintaining abstinence, addiction is perpetuated as an active choice rather than a chronic disease.
Although relapse is accepted through the 12-step process, it is viewed more as a matter of
strength and even morality rather than a physiological disease. AA does work for some people,
however, poor retention rates and serious criticisms of 12 step programs must be taken into
consideration and act as motivation in the development of holistic and collaborative models. 12
step programs are one treatment option exhorting abstinence. In contrast, harm reduction is
another treatment option which accepts drug use and implements ways to keep it as safe as
possible.
Harm Reduction
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Harm reduction is a set of principles that defines abstinence from drug use as just one of
several means of reducing drug-related problems (Lowinson 1083). The core of harm reduction
shifts the focus away from idealized long-term goals, such as abstinence from all drug use, and
re-centers importance on more attainable short-term goals which include safer behaviors
(Lowinson 1083). Because harm reduction is designed to serve drug users based on specific
individual and community needs, there is no universal definition or formula on how to carry out
these practices (Harm Reduction Coalition, “Principles of Harm Reduction”). Harm reduction is
not widely encouraged from public health officials and policy makers in fear of the message
encouraging increased drug use among current users and the creation of new users (Lowinson
1086). However, there is no direct evidence showing that harm reduction strategies such as saferdrug using practices, needle-exchange programs, or greater access to treatment increase drug use
(Lowinson 1086). Those who practice harm-reduction strategies disapprove of their drug use but
accept the inevitability of it (Lowinson 1084). Harm reduction is ultimately a social justice
movement “built on a belief in, and respect for, the rights of people who use drugs” (Harm
Reduction Coalition, “Principles of Harm Reduction”). A number of different strategies are
practiced nationwide in order to minimize harms brought about by drug use, even if the drug use
itself can’t be stopped (Lowinson 1085).
Syringe exchange programs, or SEPs, also referred to as syringe services programs
(SSP), are “community-based programs that provide access to sterile needles and syringes free of
cost and facilitate safe disposal of used needles and syringes” (CDC, “HIV/AIDS”). SEPs were
put in place in the early years of the acquired immunodeficiency syndrome (AIDS) epidemic in
the United States (Lowinson 1236). SEPs yielded benefits such as distributing information on the
risks of HIV/AIDS and helping clients connect to social and legal services as well as drug
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treatment (Lowinson 1236). SEPs have faced many challenges in the U.S. for a variety of
different reasons. There has not been enough funding, police harassment has occurred, and even
activists have been criminally prosecuted for being “caught” distributing syringes (Lowinson
1236). In fact, today many American SEPs operate illegally (Lowinson 1237). As of 2003 the
U.S. still prohibits the use of federal funds to go towards SEPs (Lowinson 1237). In reality, these
criminal sanctions create greater harm than good.
One illegal harm reduction organization continues to operate because of the devastating
number of opioid overdose deaths in the nation. The Church of Safe Injection hands out clean
drug-use supplies in eight states across the U.S., with 18 chapters in total. Bangor, Maine, is one
city represented by this church. Even though it is illegal in Maine to have more than ten
hypodermic syringes in an individual’s possession, except for certified needle exchanges, church
volunteers operate near a bus stop with free coffee, clean syringes and Naloxone (Inskeep,
“‘Church of Safe Injection’ Offers Needles, Naloxone to Prevent Opioid Overdoses”). Naloxone,
also known as Narcan, is an opioid antagonist that counters the effects of opioid overdose (Harm
Reduction Coalition, “Understanding Naloxone”). Naloxone is meant to be administered in order
to counteract life-threatening depression of the central nervous system and respiratory system,
which occurs from overdose, in order for the overdose victim to breathe normally (Harm
Reduction Coalition, “Understanding Naloxone”). One of the most significant advantages to
Naloxone is that it can be administered by minimally trained laypeople in emergency situations.
Additionally, Naloxone has no potential for abuse (Harm Reduction Coalition, “Understanding
Naloxone”). The Church of Safe Injection operates at the risk of their own volunteers’ arrests to
save the lives of others and provide alternative treatment options.

49

The founder of the Church of Safe Injection, Jesse Harvey, has worked in addiction
recovery and started the church because of his frustration by the deaths from drug use and
barriers to treatment (Inskeep, “‘Church of Safe Injection’ Offers Needles, Naloxone to Prevent
Opioid Overdoses”). Although there is skepticism around the enabling of drug use that can arise
from the availability of Naloxone, there are also questions such as, if someone isn’t able or just
not ready to go to treatment, should they die? (Inskeep, “‘Church of Safe Injection’ Offers
Needles, Naloxone to Prevent Opioid Overdoses”). Naloxone saves lives, reduces serious health
risks, and provides an alternative to dangerous drug use until a user is ready to seek proper
treatment. The Church of Safe Injection has a clear message that it does not support the
legalization of drugs (Inskeep, “‘Church of Safe Injection’ Offers Needles, Naloxone to Prevent
Opioid Overdoses”). Rather, their beliefs are centered upon moral and spiritual duties to violate
unjust laws because drug users do not deserve to die when there are so many ways to help them
(Inskeep, “’Church of Safe Injection’ Offers Needles, Naloxone to Prevent Opioid Overdoses”).
The police force of Bangor, Maine, is aware of the church and their actions but chooses
discretion over conflict because they share the same goal: to save lives (Inskeep, “‘Church of
Safe Injection’ Offers Needles, Naloxone to Prevent Opioid Overdoses”). In contrast, the police
force of Lewiston, Maine, a city located two hours from Bangor, has warned the church not to
operate there because it’s against state law (Inskeep, “‘Church of Safe Injection’ Offers Needles,
Naloxone to Prevent Opioid Overdoses”). Yet, there are only six certified needle exchange
programs in the state of Maine, none of which are in Lewiston (Inskeep, “‘Church of Safe
Injection’ Offers Needles, Naloxone to Prevent Opioid Overdoses”). Accessibility is a significant
barrier to treatment in the case of drug addiction not only in Maine, but similarly across other
states.
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Although the Church of Safe Injection can be seen as a controversial organization when it
comes to considering successful practices in combating the opioid epidemic, it focuses on one
important and primary strategy of the whole process: saving lives. Harm reduction is one initial
step that can help those suffering from OUD prepare for more holistic and long-term treatment
plans. Motivational interviewing, for example, is a patient-centered behavioral counseling
technique that positively helps people with OUD taper their drug usage and engage in healthier
lifestyles.
Motivational Interviewing
Motivational interviewing, or MI, is a form of psychotherapy developed specifically to
promote healthy behaviors (Hillman, Instructor's Resource Manual to Accompany Leslie
Frazier's Healthy Psychology). Motivational interviewing is evidence-based, client-centered
therapy designed to enhance intrinsic motivation by exploring and resolving client ambivalence
in order to promote change (Hillman, Instructor's Resource Manual to Accompany Leslie
Frazier's Healthy Psychology). An accurate and succinct way to describe MI is that the therapy
is collaborative rather than confrontational (Hillman, Instructor's Resource Manual to
Accompany Leslie Frazier's Healthy Psychology). Some of examples of MI practices include
reflective listening, rolling with resistance, and eliciting change talk (Resnicow and McMaster
5). The goal of eliciting change from within a client rather than focusing on what is right from
the therapist’s point of view builds trust and rapport between client and counselor. The therapist
aims to draw out their client’s underlying needs for change, instead of telling them why they
should change (Hillman, Instructor's Resource Manual to Accompany Leslie Frazier's Healthy
Psychology).
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Another way to describe this core principle is the difference between autonomy and
authority (Hillman, Instructor's Resource Manual to Accompany Leslie Frazier's Healthy
Psychology). Patients and clients are able to determine their own pathways in changing towards
more healthy behaviors. An autonomous technique such as this reduces client dropout rates
because of fear they might feel facing disappointment from a judgmental therapist. While MI
shows evidence of being most effective in individuals who are initially resistant to change
(Resnicow and McMaster 5), when any client is shown respect and empathy, they are more
likely to open up and be honest about their lives and behaviors (Hillman, Instructor's Resource
Manual to Accompany Leslie Frazier's Healthy Psychology). Motivational interviewing is a
successful and strengthening practice to address and combat drug addiction.
Reflective listening is one of the key components of MI. Reflective listening allows the
counselor to portray to their client that they have understood what they said, affirm what the
client is feeling and thinking, importantly without judgment, and help the client dig deeper into
their process of self-discovery (Resnicow and McMaster 5). Reflective listening statements begin
with phrases such as, “Given what you said about…” or “It sounds like…” (Resnicow and
McMaster 5). The use of these phrases first allows the counselor to summarize what they
understood the client shared with them, gives space to clarify or correct any misunderstandings,
and ultimately allows the client to reflect on what they are feeling or experiencing with support
from their counselor. Reflective listening is beneficial because it eliminates bias that could come
from the therapist with questions that stem from their interest or experience rather than the
client’s (Resnicow and McMaster 5). Reflections can have several levels of complexity and
depth, but each step holds the purpose of building trust amongst client and counselor and guiding
the client to deeper self-discovery and understanding.
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Rolling with resistance is another core technique of MI. To roll with resistance means
that the therapist refrains from personal urges of concern and telling the client what to do
(Hillman, Instructor's Resource Manual to Accompany Leslie Frazier's Healthy Psychology).
“Dancing” with the client rather than “wrestling” with them is an illustrative analogy to represent
rolling with resistance (Hillman, Instructor's Resource Manual to Accompany Leslie Frazier's
Healthy Psychology). Rolling with resistance is all about refraining from judgment. The client
can feel comforted rather than confronted. Rolling with resistance is essentially agreeing with the
client even if the statement is not the healthiest behavior or is factually incorrect (Resnicow and
McMaster 5). Examples of practicing rolling with resistance are affirmations such as, “You
really enjoy smoking weed. Giving it up seems very difficult,” or “Eating at McDonald’s is a real
treat for you. It’s cheap, convenient, and really works given your busy schedule” (Resnicow and
McMaster 5). These phrases are shared without judgment or negative confrontation.
Rolling with resistance is a practice of MI that captures the client’s inability to change
and allows them to express their resistance without pressure or judgment to change (Resnicow
and McMaster 5). Instead of criticizing the client’s negative behaviors, the counselor can help
the client learn to acknowledge and celebrate small successes, which are motivations to keep
moving forward (Hillman, Instructor's Resource Manual to Accompany Leslie Frazier's Healthy
Psychology). Even if a client’s efforts don’t result in success, the goal is to celebrate
commitment rather than view it as failure (Resnicow and McMaster 5). Every step, no matter
how small, is key in any client’s treatment path and should be recognized. Rolling with
resistance is an essential part of MI to fully understand a client’s current unhealthy behaviors in
order to figure out the best way to change them towards healthier behaviors.
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Overall, MI yields more positive treatment outcomes, a better quality of life for patients,
stronger client engagement and treatment retention, and further, increased staff satisfaction and
job retention (Lecture 3.1). MI is a mutually beneficial technique for both counselors and clients.
While specific, individual MI techniques can vary across counselor-patient relationships, there
are four underlying principles of MI that shape the practice: empathy, identifying discrepancies,
rolling with resistance, and supporting self-efficacy (Hillman, Instructor's Resource Manual to
Accompany Leslie Frazier's Healthy Psychology). Motivational interviewing is a successful first
intervention method for client’s battling addiction, and an important way for patient and
counselor to establish a positive relationship. MI is used in many comprehensive treatment
programs for addiction.
Comprehensive Approaches
In 2015, an evaluation of 13,000 substance abuse treatment facilities across the United
States found that only 40% offered women-centered programming and 81-95% of women had an
unmet need for women-centered treatment services (Krans 5). Many of the problems that exist
around treatment for women in the U.S. have been ongoing for several decades. For example, a
literature review on current treatment systems for pregnant and parenting women with SUDs
from 1993 identifies many similar problems society continues to face today in regard to
treatment connection. This review highlights that “during the 1960s and 1970s, opiate addiction
in pregnant women became a cause for concern,” further emphasizing how opioid addiction and
women of reproductive age is not a new dilemma in American society (Finkelstein 1276). One of
the main goals of this review is to emphasize the vast literature base that exists that should aid in
developing successful treatment programs which include women. Finkelstein identifies that
many treatment models are either male or individual-based, failing to take into account the needs
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of women, pregnant women, and mothers with children (1280). Finkelstein observes that
comprehensive care programs are the most effective models and identifies guidelines for care
based on an analysis of existing comprehensive programs. These guidelines include programs
that are family-centered, women empowering, community-based, utilizing coordination and
collaboration of services, multi-dimensional, unique and sustained, and ranging in levels of care
(Falletta 1286-1289). Falletta includes a table comparing the existing comprehensive treatment
programs of the time, highlighting which services they did or did not offer, but does not go into a
more in-depth analysis. The table is composed of 9 programs, followed by suggestions for
improvement within comprehensive models and which areas require the most emphasis.
Falletta’s review provokes many areas of discussion in regard to comprehensive treatment
approaches for women of reproductive age and the opioid epidemic.
Although outdated, this review provides valuable insight into important elements of a
comprehensive care model, an identification of the lack of focus dedicated to pregnant and
parenting women that remains today, and a discourse around the persistence of barriers to care
that have not been settled in current society. It was innovative for Falletta to identify current
comprehensive programs for pregnant women with SUDs, but disadvantageous to exclude an
analysis of them. The literature base can be vast in supporting the launch of successful, longterm treatment programs, however, specific reviews of current and past programs and their
unique failures and successes are also crucial in the continued development of holistic models.
Falletta’s identification of components necessary for comprehensive models is important, as well
as the recognition that “there is not necessarily a single blueprint for a successful treatment
program” (1292). Ongoing analyses and conversations about successful programs, failed
programs, and all the methods in-between are essential in maintaining the truth that not one size
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fits all. Society must be dedicated to providing coordination of care services that can fit the needs
of many individuals.
Bernstein et al. conducted a study testing brief motivational intervention during a clinic
visit in regard to reduction in out-of-treatment cocaine and heroin use (Bernstein 49). The
investigators aimed to test abstinence from cocaine and/or heroin at 6-months post-enrollment
(Bernstein 50). Their measure of abstinence came from a hair drug test (Bernstein 50). This
study was a randomized controlled trial and took place in the outpatient clinics of an urban
teaching hospital (Bernstein 49). The structure of the study’s motivational intervention included
five bilingual peer coaches, who were trained CHWs in recovery themselves, three of whom
were the principal interventionists and the other two acted as research assistants (Bernstein 50).
Incentives were included for participation in this study, in which all participants received a
reimbursement of $15 at the time of enrollment, $25 for the first follow-up visit, and $35 for the
second follow-up visit (Bernstein 52). Interestingly, the results of this study reported “relatively
good agreement between self-reported [drug] use and biochemical test results at baseline”
(Bernstein 54). Motivational intervention practices that were utilized in this study included trust
building, conforming to the patient’s preference on readiness for change, conversations around
the advantages and disadvantages of drug use, as well as about goal quality of life (Bernstein 52).
The authors of this study ultimately concluded that “brief motivational intervention in the
clinical setting can reduce heroin and cocaine use” (Bernstein 58). Although not specific to
pregnant women, positive motivational intervention practices for individuals with OUD are
important in the discussion of the most successful treatment programs. The limitations of this
study’s usage of MI techniques and reimbursements is important to consider in developing
efficient comprehensive models.
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One of the greatest limitations of this study is the speculation that potential participants
are solely seeking reimbursement in return for participation. Money in the form of cash could in
theory help people battling SUDs obtain their immediate needs, whether it be food or
transportation, however investigators are usually extremely cautioned when utilizing the element
of incentives when it comes to research designs. It is better to offer incentives in the form of
material goods clients could really use, such as car seats or bus vouchers, instead of directly
handing cash to the participants. This could skew the motives of participation and the results of
any study, such as the case in this research which found “self-report of improvements in drug use
in this sample was shown to be highly inflated” (Bernstein 57). Incentives can be an important
element of research studies, most significantly because they can offer clients expensive items
which the study otherwise would not be able to offer them, however the design needs to be
executed in such a way that clients are receiving the most benefits possible. To conclude, the
data from this investigation exemplified that contact with peer coaches in recovery who also held
important hospital jobs “may have served as a powerful motivating example for both groups”
(Bernstein 58). Future comprehensive models can learn from the risk of using incentives and
build on the success of peer addiction recovery coaches.
Recovery coaching has a lot of supportive data for success in many aspects of society,
such as reduction in drug use, legal involvement and costs. The Vermont Recovery Network
released a report summarizing findings on recovery coaching at one of the Vermont Recovery
Network’s Recovery Centers. Although a small sample size of 52 individuals, the data reported
found “a potential for recovery coaching to reduce social costs associated with addictive and cooccurring disease,” a reduction in the use of detoxification programs paired with hospital and ER
visits, as well as an increase in use of primary care providers (Kamon and Turner 2). This report
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also stated that participants disclosed 118 sober days from alcohol and other drugs at the start of
Recovery Coaching (Kamon and Turner 3). Recovery coaching has had successful initial results
which is important for the development and deployment of future resources. Furthermore, “the
use of costly services such as hospitals, emergency rooms, and detoxification programs
decreases” (Kamon and Turner 4). The findings of this report portray optimism but emphasize
the need for future research that investigates these advantages across unique populations and
different sample sizes.
Additional to the need for accessibility of comprehensive treatment programs that
holistically treat individuals, specifically women of reproductive age, is close attention not to
duplicate resources but instead to coordinate differing care services. Shepherd-Banigan’s study
investigating the question of whether or not maternity care coordination services encourage use
of behavioral health treatment amongst pregnant women on Medicaid brings significant attention
to this issue (Shepherd-Banigan 449). According to Shepherd-Banigan and her team, Maternity
care coordination (MCC) “is a program run by local health departments that connects Medicaideligible women to services and education” (449). Shepherd-Banigan and her investigative team
focus on the comorbidities of substance use disorders, specifically mental health illnesses, and
argue that MCC is an opportunity to increase access to behavioral health treatment services.
According to the study authors, “The most widely recognized mental health disorder is perinatal
depression” (Shepherd-Banigan 450). Depression during the pregnancy process is a struggle any
woman can be susceptible to, and an intense yet under-focused problem in the health care field.
Importantly, depressive symptoms before and after birth are directly correlated with
substance dependence during the postpartum period (Shepherd-Banigan 450). Therefore,
comorbidities and an aim to coordinate care services are crucial in comprehensive treatments for
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women of childbearing age. Shepherd-Banigan’s study examined a random sample of 8,000
women from Medicaid claims in North Carolina. Ultimately, the researchers conclude that
“MCC may present an opportunity to build on maternal motivation and, in conjunction with
sufficient system supports, engage pregnant women in behavioral screening and treatment
services” (Shepherd-Banigan 453). Not only does coordination of care services avoid duplicating
efforts, it can connect women to the comprehensive care they need for a range of difficulties that
accompany SUDs.
There is an overwhelming amount of comprehensive treatment models that have either
been developed or both developed and deployed, as well as published for the betterment of the
health care community and society. It has been established that women in general, but especially
pregnant women, have been largely excluded from a lot of important research and only the
central focus of a minority percentage of treatment programs because of stigma and legal
barriers. Ultimately, a comprehensive treatment model is going to be the only successful solution
to reduce the burden of the opioid epidemic for women and children. The evaluation and
alteration of preexisting comprehensive models, both for the general population and specifically
for women, must be taken into account for the development of future programs. The solution to
such a complex and intense problem becomes increasingly hard to answer through the
acceptance that no one size can fit all. However, the understanding of methodologies such as the
use of recovery coaches and coordination of care services are elements that are going to be the
most beneficial in creating a largely successful, holistic, long-term treatment program that is
flexible to the needs of unique women and their children.
The Peer Model
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Even with the presence of pharmacological and comprehensive treatment programs, legal
barriers, including mothers’ fears of having their children taken away, rejection from clinical
programs, financial status, accessibility to treatment facilities, possibly even intimate partner
violence are all serious deterrents that persistently push women with OUD away from the care
they and their newborns need. Valerie Chandler, former program director of the Berks Parents
Services Collaborative Program, puts herself in the shoes of a mother with OUD and succinctly
sums up a looming threat they face:
So, you’re a new mom. You were using opiates, and now, you know, the hammer’s
coming: The county’s coming to get you; your family is going to be all over you. You’re
going to lose this child, and you screwed up. Throw in some new-mom hormones,”
Chandler says, “and you’re a basket case. Oh, and by the way, don’t use drugs anymore.
Right? Your one coping skill is gone. (Chatterjee and Davis, “Beyond Opioids: How A
Family Came Together To Stay Together”)
Mothers with OUD fight this nearly unwinnable battle all the time. The blatant lack of support
perpetuates the high percentage of addicted women not receiving treatment. Her community is
abandoning her, her family is giving up, her new baby has to leave her, and she is faced with the
prospect of quitting the one thing that has helped her cope: her addiction. Society expects women
to fight the many battles that come with opioid addiction all on their own. This lack of
understanding addiction leaves a huge gap in not only women-centered support services, but also
generally in sufficient human resources, leaving too many women and their children alone and
uncared for. Women of reproductive age are lost and left with questions about whom to trust
when it comes to caring for their babies and themselves. However, all it takes is one person to
believe you. Community intervention methods that utilize peer addiction recovery coaches are
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new, successful ways to help women of reproductive age with OUD navigate the resources
available to them while improving both their and their babies’ health in a safe, understanding
environment at a pace comfortable for the woman.
The peer recovery intervention worker is similar to the community health worker which
is shown to be effective in multiple health care and public health settings (Watson 16).
Community health workers (CHWs) are lay people in communities trained to provide some part
of health services (Mutamba 1). Lay community health workers (LHWs) are used to fill the gap
left by a lack of sufficient human resources in the public sector and to link communities to the
formal health services through “task shifting” (Mutamba 1). LHWs are utilized in the recognition
that service needs, particularly in remote and underprivileged communities, are not met by
existing health services (Mutamba 1). The use of LHWs has been significantly successful in
many low- and middle-income countries (LMIC), such as India and South Africa. The key
profile of an LHW is that their training is relatively informal. It does not form part of a tertiary
education certificate (Mutamba 2). Education levels of LHWs can range from limited schooling
with the ability to read and write to completion of secondary school or university education
(Mutamba 2). This purposeful minimalized training strategy is used because LHWs can be
deployed faster, as well as their services complement and support those provided by other health
workers (Mutamba 2). Peer workers can be volunteered or paid. In many LMICs, LHWs are
often volunteers elected by community members. Because of the peer recovery model, there
have been several improvements in substance use treatment exemplified in different societal
aspects.
Utilizing peer coaches in health care settings not only helps fill many gaps within the
health care system, community worker and client relationships can start off successfully just on
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the basis of the level of understanding that can preexist. For example, as mentioned, CHWs are
elected by other community members in certain countries and cultures, or they are hired based on
their unique backgrounds and experience with different community groups. CHWs can have
their GEDs or a college education. They key characteristic that makes the use of CHWs so
successful is that they possess not only an understanding of what their targeted clients
experience, but an empathy for them because of their own personal experience. CHWs are hired
and deployed because of their commitment to their job and their patients, their abilities to
understand, and the mindset to see success in every effort and even failure. Clients and CHWs
themselves have had many profound and significant experiences in these relationships that could
never be replicated in a traditional medical setting.
Angelina Rivera Richart, a parent mentor engaging in the peer recovery model, truthfully
paints the picture of the positive effect of community engagement:
On the second day, I met Ruth Taylor who facilitated a weekly parent support group.
Ruth believed in me when no one else did, until I could believe in myself…I started to
believe in myself and realize that I was my best advocate; I had the power to change my
life story. (Taylor 20)
Peer addiction recovery is the key for many women and their children’s path to a healthy
lifestyle by overcoming many barriers posed by society.
Because maternal substance use is associated with a range of environmental factors that
are risks for healthy child development, such as mental health problems, poverty, unstable
housing and more, the postpartum period is a critical factor in child outcomes and when many
women resume substance use (Watson 16). The Peer Recovery Worker Intervention Model is an
evidence-informed home-visiting practice that employs staff with backgrounds that mirror those
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of their clients to engage and support pregnant women and mothers of substance-exposed
newborns. (Watson 15). Peers working with pregnant and postpartum women have promoted a
vast number of positive health-related outcomes, such as positive maternal health outcomes,
infant health, and positive interaction between mother and child, longer breastfeeding, and
prevention of unplanned repeat pregnancies (Watson 15-16). Peer recovery intervention workers
provide emotional support, linkages to resources and assistance in maintaining and/or beginning
substance use treatment (Watson 16).
Arguably, the most significant attribute of the peer recovery worker is their ability to
empathize with their clients. Although not all recovery coaches are in recovery themselves, a
coach’s personal relationship with addiction of their own, a family member or loved one
provides them the unique ability to engage with and empower women, increasing the use of
substance use treatment services and promoting relapse prevention (Watson 16). A Helping
Hand: Mother to Mother (AHH), a project of the Massachusetts Department of Public Health and
Project Family Early Advocacy and Treatment (FEAT) in Lane County, Oregon, both have goals
of providing comprehensive care for substance-exposed newborns and their families and view
peers as a central part of their project (Watson 15). Peer recovery workers intervene as a bridge
between barriers associated with legal services, such as child welfare, and coordinated care for
women of reproductive age struggling with addiction.
Whether an addiction recovery coach or a general community health worker, these peer
coaches add something to the health care world that no medical setting could ever achieve, which
is consistent support. Peer coaches are employed and target a specific population that has
endured different kinds of adverse childhood experiences (ACE) and have not experienced
human attachment in a healthy way. Peer coaches work with clients who push them away and
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indicate a lack of trust because of their past, which makes establishing trust between coach and
client a major process in the peer model. Peer coaches give patients what general doctors and
nurses cannot, from home visits to responsiveness that encourages continued participation and
meetings. The main messages that peer coaches aim to send to their clients is “I’m here for you,
I’m not going away, and I understand what you are going through.” Patients will not experience
any wait periods or rejection that might come with traditional medical settings. CHWs add a
level to health care that is unique and successful in not just filling gaps but improving the health
of communities at large.
Meeting the treatment demand of the opioid epidemic is one of the hardest obstacles that
society is battling. Accessibility, adherence, stigma, and legal barriers are the main deterring
factors preventing women of reproductive age from getting treatment. Analyzing these elements
and providing solutions as to how to overcome them is a key step in fighting the opioid
epidemic. CARE Plus is a peer-based treatment program that operates progressively and aims to
offer the most holistic services available. CARE Plus has built the essential components to
understanding and treating the opioid epidemic into its core values, such as understanding
addiction as a chronic disease, overcoming stigma, accepting relapse as a part of treatment,
focusing on reform rather than punishment, and including children in treatment. While not
perfect, CARE Plus is a significant step towards progress in comprehensively battling the opioid
epidemic. Reaching vulnerable and isolated women, CARE Plus helps women battle their
addictions while also focusing on their health as a whole.
CARE Plus: A Community-based Addiction Reduction plus Policy
Indianapolis, Indiana intensely battles the opioid epidemic like many other cities across the
U.S. The number of babies born with NAS is steadily climbing. According to unpublished data
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from the CARE Plus grant, in 2016 over 450 infants were born with NAS in Indiana (SAMHSA,
“Substance Abuse Treatment: Addressing the Specific Needs of Women”). “In 2017, nearly 500
infants with NAS were born in [Indianapolis,] Indiana, 160 of whom were delivered at Indiana
University Health (IUH) Methodist Hospital” (Litzelman and Chambers 2). This number
represents a 12% increase from 2015 (Litzelman 2). Furthermore, treatment options are very
limited. In Central Indiana there are only two methadone clinics. Because many women who
receive a prescription for MAT from their obstetrician during pregnancy lose Medicaid coverage
after delivery, they are extremely vulnerable to relapse (Litzelman 3). A critical need exists for
greater accessibility to treatment in the Indianapolis area. While significant steps have been made
to increase treatment options and coverage for women of all backgrounds across Indiana and the
United States, a large gap still exists between demand and sustainability. CARE Plus, an
innovative, Community-based, Addiction Reduction plus Policy Innovations Program for
Indiana is a pilot program with the purpose of filling the defined gap with resources to provide
tools for women with OUD to best care for their infants (Litzelman and Chambers 2). CARE
Plus aims to keep women in treatment and help mothers and their infants lead healthy lives.
The CARE Plus program team applied for and was awarded a grant from the Richard M.
Fairbanks Foundation of Indianapolis. They are an extremely new program, just beginning
official operations around January 2019. CARE Plus builds on two existing community
partnership programs, WeCare and Circle of Security-Parentingã (COS-P). WeCare is a
combination of “health care, public health, and community organizations that aims to reduce
infant mortality in Indiana’s Central and Eastern Regions though outreach, health coaching,
community engagement, and mobile health (mHealth) messaging technology” (Litzelman and
Chambers 4). WeCare deploys community health workers (CHWs), lay workers who serve as
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peer coaches and organize mHealth messaging, to offer “trusted, timely, and on-going support
and guidance to women considered at-risk for poor pregnancy and/or post-partum outcomes”
(Litzelman and Chambers 4). In comparison, COS-P is an “evidence-based, therapeutic
intervention for parents, including addicted mothers, which has demonstrated improvements in
parental reflective abilities, post-partum depression, and attachment security between parents and
their children” (Litzelman and Chambers 4). CARE Plus builds on WeCare and COS-P in
partnership with IDEO, a human-centered design team, to successfully meet the unique,
individualized needs of mothers with SUDs, opioid use disorder in particular. A focus on the
attachment process in mother-infant dyads and resource connection and coordination are two
crucial components of CARE Plus. The main goals of CARE Plus are to improve mental health
treatment access and engagement in long-term substance abuse treatment, improve long-term
outcomes of mothers with OUD and their infants, and ultimately develop a better understanding
for psychological, social and biological factors that contribute to outcomes of interventions with
mothers with OUD and their infants.
CARE Plus utilizes the peer-structured model with the training and deployment of
addiction recovery coaches (ARC) to recruit and maintain relationships with mother/infant
dyads, in which the mother has OUD and their infant was born with NAS. Addiction recovery
coaches are similar to community, or lay, health workers (CHW/LHW), with additional training
in addiction recovery and personal experience with addiction. It is not crucial that an ARC has
battled addiction personally, but important that they have had an intimate experience with
addiction, with a family member or loved one, for example. Currently CARE Plus has two fully
trained and certified ARCs, with three more coaches waiting to take their official certification.
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The second core component of CARE Plus is the Circle of Security-Parentingã attachment
process. The ARCs’ goals are not to “cure” their patients’ addictions. Because of the qualitative
knowledge learned from WeCare as well as COS-P, mothers who struggle with addiction have
most likely had a negative life experience concerning trust, which can affect their attachment
process to their infant. ARCs are sources of consistent attachment and aim to provide neverending support for their clients. They understand and empathize through motivational
interviewing practices that advance patients towards healthy life goals and attempt to provide the
easiest coordination and connection to resources for women that will never run out. The program
coordinators of WeCare, COS-P, CARE and CARE Plus through experience and research have
learned that the best coaches take the recruitment and treatment process slow. The coaches first
develop a relationship with a potential participant through four to five encounters before even
introducing the program, enrollment protocol and benefits for the women. The relationships
culminated through peer coaches and patients are unique because they are unattainable in a
traditional medical setting, but they produce significant levels of success in high-risk
populations.
One of the overarching goals of CARE Plus is to normalize addiction care into the health
field just as any other treatment of a chronic illness, such as diabetes or cancer. People struggling
with SUD are just like anyone else, they have an area of their health that needs individualized,
long-term treatment. CARE Plus also focuses on the stress of parenting with COS-P, a part of
motherhood or fatherhood that every parent experiences, not just individuals who might be
struggling with a SUD. One of the most difficult things to overcome in today’s society is making
the point that all mothers go through hardships and that a comorbidity such as postpartum
depression, for example, can affect anyone. However, CARE Plus is dedicated to sending the
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message that struggling does not define a bad mother in order to establish trust and empathize.
CARE Plus aims to level addiction on the same plane as diabetes medicine, food insecurity,
housing insecurity, mental health, all inequalities and health disparities that affect large
populations in America. The core values of CARE Plus are that there is no shame, no blame, nor
guilt in seeking and receiving treatment and assistance for anything. Despite CARE Plus being a
pilot program, its foundational research and holistic, fundamental values can result in a
successful and effective treatment program.
A crucial additional element of CARE Plus is also “coaching the coaches.” Health worker
burnout is highly plausible and common, especially in employees working so closely with their
patients, on irregular schedules, and with serious cases such as addiction or domestic violence.
Several studies support the claim that health care workers “are exposed to a variety of severe
occupational stressors, such as time pressure, low social support at work, a high workload,
uncertainty concerning patient treatment, and predisposition to emotional responses due to
exposure to suffering and dying patients” (Portoghese 152). Health workers are at risk for
burnout on a uniquely sensitive level. A focus of the CARE Plus team is to save time for
discussions that focus on the coaches rather than the patients, and to practice teamwork in
developing solutions for particularly hard situations. Coaches also need reassurance along with
their patients if relapse occurs, for example, that they did not fail and that it happened as part of
the treatment process. A program that considers the wellbeing of all participants involved is well
structured for long-term overall success.
CARE Plus just began official operations in January of 2019. There is not currently published
nor sufficient data to work with, however the principal investigator (PI) of the study, Dr. Debra
Litzelman, has theorized about the prevalent trend in lacking retention for CARE Plus at two
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months. Currently, in order to gain traction for the program, the protocol for enrollment to gain a
solid number of participants is for a research assistant to enroll women at IU Health Hospital. Dr.
Litzelman speculates that once they have more certified ARCs to recruit, and that the ARCs are
establishing relationships with women participants from the start, retention rates will increase.
As of March 2019, CARE Plus has 7 mother/infant dyads, and has recorded 3-4 refusals. The
general rule of thumb with refusals for this program is if after three attempts the woman is
confident in her decision not to participate, the research assistant or health coach will cease
contact. However, it is not uncommon that potential candidates take time to think about enrolling
or express insecurities about participation. At this point, the unique role of the health coach can
prevail successfully by starting to build trust with the client and making sure she is aware of all
the benefits that will result from the program. CARE Plus will be a fascinating model for
evaluation when the program is truly underway, even just at six months operating.
While it is currently difficult to determine the true potential for CARE Plus, based on the
success of WeCare, COS-P and the urgent treatment demand in regard to the opioid epidemic,
the Indianapolis community can be optimistic about this pilot program. More cities nationwide
need to launch similar pilot programs that aim to fill resource gaps and treat addiction on a more
intimate level. It is important that communities are not duplicating efforts but providing ways in
which available resources can be connected to the right people in an efficient process.
Minimally, CARE Plus is a way to empower women and bring communities together utilizing all
resources to combat the opioid epidemic. Expectedly, CARE Plus can serve as a model or
inspiration for future treatment programs.
“Beyond Opioids”: Enacting Momentous Change in American Society
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Ultimately, this literature synthesis has argued that women of reproductive age and
children are two of the most important and crucial populations of the opioid epidemic.
Furthermore, this paper examined the advantages and disadvantages of the different approaches
to treatment for women of reproductive age battling OUD and their children. The notion that
“one size fits all” has been strongly refuted. The opioid epidemic is a wave of a drug crisis that
cannot be evaluated as one singular problem. There are a staggering number of elements that are
associated with substance abuse, including the fact that opioids are not the worst nor the end of
drug use catastrophes in America. America needs to critically consider its drug policies and
negative criminal punishments following illicit drug use. If addiction were viewed more widely
as a chronic disease, by more areas than just the health care field, this belief would assist in
developing alternative treatment programs for all people battling SUD. In consideration of the
treatment demand gap and low efficacy of existing approaches, it is arguably disappointing that
there is a small minority of holistic and comprehensive treatment programs that are specific to
women of reproductive age. The preexisting models, no matter how successful, however, can act
as examples for the rest of the country and motivate the addition of many more programs. There
is so much unknown and at risk with the long-term cognitive, social and academic consequences
of the opioid epidemic on women and children. Society has already overloaded existing
resources and organizations, such as the foster care system, and needs to look more seriously at
preventive methods. Therefore, accessibility to efficient and successful treatment must be the
utmost concern for American institutions and society at this point in time.
The encompassing goal of this literature synthesis was to argue for a change in
understanding of addiction amongst the general population. Although many areas of the health
care field accept addiction as a chronic disease, the rest of the nation does not necessarily agree.
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It is not so simple to argue that addiction is just like any other chronic disease, like diabetes or
hypertension; a shift has to occur in society to continue to allocate resources to drug epidemics
with this perception in mind. Conclusively, what is going to save the lives of women and
children everywhere is a decrease in legal restrictions and the implementation of reformatory
policies and programs. Dr. Debra Litzelman, PI of CARE Plus, puts the innovative ideology of
addiction in brief yet truthful words: “No shame, no blame, no guilt.” Although this is in
opposition to the norms of American society, it is the necessary change that is going to save the
lives of thousands of women and children.
Limitations
There are limitations to this review that need to be addressed. Firstly, this literature
synthesis could not encompass all of the data and studies available in specific regard to women
of reproductive age and substance use. As an individual student conducted the research, literature
review, and publication drafting singularly, the timeframe of less than seven months was not
suitable to conduct an overarching systematic review of all the published literature related to this
topic. Furthermore, the opioid epidemic is an ongoing public health crisis, with new information
arising every day. This synthesis could not include all of the most current data surrounding the
epidemic.
A second limitation to discuss is the student author’s background. With minimal
experience in the science and medical field, it is important to keep in mind that the student
interpreted scientific studies to the best of her ability. Her background in Global Health, with
small concentrations in Anthropology and Sociology, allowed an advantage for her to evaluate
the human-centered elements of the crisis. Sections discussing the pathophysiology of NAS and
addiction were produced from the investigations of primary sources. Her experience on an infant
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mortality reduction study, WeCare, as mentioned in the CARE Plus section, however, allowed
for personal and local insight on the epidemic in a specific rural location of the U.S. The
student’s expertise is important to take into account when critiquing the literature synthesis.
Finally, this literature synthesis was limited to a national drug problem. The war on drugs
was not discussed nor largely researched to contribute to data on an international dilemma.
Furthermore, a discussion of international models was not included. This can be seen as a
disadvantage through the exclusion of potential successes and learned failures from experiences
in other countries. An analysis of the international approach to drug abuse will ultimately be very
important in determining one of or some of the best approaches to treatment for some of the most
remote populations.
Future Research
The conclusions of this literature synthesis suggest that CARE Plus should be evaluated
by external organizations minimally at six-month and one-year checkpoints. Progress can be
analyzed, and other models can be considered in different areas of the U.S. that utilize CARE
Plus’s successes. It would be irresponsible to think that America is going to eradicate opiate drug
use, therefore a semi-constant evaluation and development of new treatment models must be part
of the plan. The nation cannot fall into a similar pattern of immobility, as has been analyzed with
the failure of the Prohibitionist Model. Dr. Ciccarone, a credible opioid epidemic expert,
succinctly describes how harmful the opioid crisis has become, by labeling it as an “out of
control epidemic” (Brown, “The Opioid Crisis is Driven by Prohibition”). What is most difficult
to comprehend is that the opioid epidemic is not the end. Dr. Ciccarone rationalizes, “We need to
treat it like a rolling epidemic. Three waves and now we’ve got a fourth wave coming, and for
that we need real time data, on the ground, direct observation, and courageous out of the box
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solutions” (Brown, “The Opioid Crisis is Driven by Prohibition”). The fourth wave he refers to is
the disconcerting fact that stimulants such as cocaine are drugs that are going to directly follow
the opioid epidemic if policy and legislation continue to operate years behind current data. These
facts can be directly related back to the Prohibitionist Model of America, which has been rooted
in society despite its many national and international failures. Society cannot afford any more
time or mistakes. Now is the time to start not only adopting change but enacting it.
The “courageous out of the box solutions” Dr. Ciccarone refers to are exactly the kind of
solutions necessary to facilitate significant change in American society. It could be argued that
one of the most difficult things to achieve, even more so than deploying enough accessible
successful treatment programs, is first adapting the way society perceives addiction and
individuals who battle SUD. Addressing societal roots is not an easy nor immediate task,
however the more discussions that occur and the more suggested novel treatment programs that
are proposed are ways to push communities towards different ways of thinking and operating. In
the interest of women of reproductive age specifically, these shifts should have happened years
ago. Future research must be intense in order to get the legal system, the health care field, the
government, and entire communities on new and improved pathways to combating the opioid
epidemic.
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Appendix
Acronyms
AA

Alcoholics Anonymous

ACE

Adverse childhood experience(s)

AHH

A Helping Hand: Mother to Mother

AIDS

Acquired immunodeficiency syndrome

ARC

Addiction recovery coach

ASAM

American Society of Addiction Medicine

CA

Cocaine Anonymous

CARE

A Community-based Addiction Reduction

CDC
CHW

Centers for Disease Control and
Prevention
Community health worker

CMA

Crystal Meth Anonymous

COS-P

Circle of Security-Parenting

CPS

Child protective services

DSM
FEAT

Diagnostic and Statistical Manual of
Mental Disorders
Family Early Advocacy and Treatment

FDA

Food and Drug Administration

HA

Heroin Anonymous

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

IUH

Indiana University Health

LHW

Lay community health worker
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LMIC

Low- and middle-income country

MAT

Medication-assisted treatment

MCC

Maternal care coordination

MI

Motivational interviewing

MMT

Methadone maintenance therapy

MOTHER
NA

Maternal Opioid Treatment: Human
Experimental Research
Narcotic Anonymous

OUD

Opioid use disorder

PI

Principal investigator

NAS

Neonatal abstinence syndrome

NPR

National Public Radio

SAMHSA
SEP

Substance Abuse and Mental Health
Services Administration
Syringe exchange program(s)

SSP

Syringe services program(s)

SUD

Substance use disorder

TB

Tuberculosis

WHO

World Health Organization
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